University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2022

Regulation Of The Tubulin Code In Cardiac Hypertrophy And
Failure
Sai Aung Phyo
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Cell Biology Commons, Molecular Biology Commons, and the Physiology Commons

Recommended Citation
Phyo, Sai Aung, "Regulation Of The Tubulin Code In Cardiac Hypertrophy And Failure" (2022). Publicly
Accessible Penn Dissertations. 4739.
https://repository.upenn.edu/edissertations/4739

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/4739
For more information, please contact repository@pobox.upenn.edu.

Regulation Of The Tubulin Code In Cardiac Hypertrophy And Failure
Abstract
A proliferated and post-translationally modified microtubule network underlies cellular growth in cardiac
hypertrophy and contributes to contractile dysfunction in heart failure. Yet how the heart achieves this
modified network is poorly understood. Determining how the “tubulin code” – the permutations of tubulin
isoforms and post-translational modifications – is rewritten upon cardiac stress may provide new targets
to modulate cardiac remodeling. Further, while tubulin can autoregulate its own expression, it is unknown
if autoregulation is operant in the heart or tuned in response to stress. Here I use heart failure patient
samples and murine models of cardiac remodeling to interrogate transcriptional, autoregulatory, and
post-translational mechanisms that contribute to microtubule network remodeling at different stages of
heart disease. I find that autoregulation is operant across tubulin isoforms in the heart and leads to an
apparent disconnect in tubulin mRNA and protein levels in heart failure. I also find that within 4 hours of a
hypertrophic stimulus and prior to cardiac growth, microtubule detyrosination is rapidly induced to help
stabilize the network. This occurs concomitant with rapid transcriptional and autoregulatory activation of
specific tubulin isoforms and microtubule motors. Upon continued hypertrophic stimulation, there is an
increase in post-translationally modified microtubule tracks and anterograde motors to support cardiac
growth, while total tubulin content increases through progressive transcriptional and autoregulatory
induction of tubulin isoforms. My work provides a new model for how the tubulin code is rapidly rewritten
to establish a proliferated, stable microtubule network that drives cardiac remodeling, and provides the
first evidence of tunable tubulin autoregulation during pathological progression.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Benjamin L. Prosser

Keywords
Autoregulation, Cardiology, Microtubules, Transcription, Tubulin Code

Subject Categories
Cell Biology | Molecular Biology | Physiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4739

REGULATION OF THE TUBULIN CODE IN CARDIAC HYPERTROPHY AND FAILURE
Sai Aung Phyo
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2022

Supervisor of Dissertation
Benjamin L. Prosser, PhD
Associate Professor of Physiology

Graduate Group Chairperson
Daniel S. Kessler, PhD
Associate Professor of Cell and Developmental Biology

Dissertation Committee
Mark L. Kahn, MD, Edward S. Cooper, MD/Norman Roosevelt and Elizabeth Meriwether McLure
Professor
Edward E. Morrisey, PhD, Robinette Foundation Professor of Cardiovascular Medicine
Eric F. Joyce, PhD, Assistant Professor of Genetics
Joel D. Boerckel, PhD, Assistant Professor of Orthopaedic Surgery

To my mom and my aunt without whom I would not be writing this

ii

ACKNOWLEDGMENT

To my advisor and mentor, Ben: Over the past four years, it has been a great pleasure
learning with you and working for you through the thick and thins of life and science.
During my time in your lab, you constantly challenged me to think critically of my science
and aspired me to be a better scientist who is not daunted by any question. At the same
time, you give me time and space to find my identity which has allowed me to grow into
an individual, and for all of those, I am eternally grateful. Thank you so much for not only
being my scientific mentor, but also for being a genuine person who is always willing to
lend me an ear through tough times.

To my mom and my aunt: I am sure you will not probably see this unless I show you, but
this section would not be complete without you two. Although we have been away from
each other so long, your constant unwavering supports make me feel as if we live right
next to each other. Thank you and love you both so much.

To former and current Prosser Lab members: From providing me with great camaraderie
to helping me with experiments and helping make sense biology, you all made my time
in lab the best possible. Special shoutouts to Keita for always willing to mentor, talk,
laugh, and help me in any way you possible could, and to Emily and Alex for making my
days in lab more joyful.

To my thesis committee members: I could not have done this without your input and your
desires to push me to be a better scientist. Thank you very much for always keeping my
best interest at heart and for always nudging me in the right direction to get my PhD.
iii

To Dr. Carter and Dr. Vancurova: Without whom, I would not even be in science. Thank
you, Dr. Carter, for seeing potential in me, for being my first mentor in the US, and for
continue believing in me during the dark times of my training; I am very lucky to still be a
part of your life and I am always looking forward to seeing you again soon. Thank you,
Dr. Vancurova, for taking a chance in me and for letting me work in your lab during my
undergraduate years; you showed me the joy of doing amazing science with a great
team and it is the experiences in your lab that you fostered that made me chose the path
I am on.

Finally, to my friends, family, and past teachers: I miss you all dearly and even though
we might not be in constant contact, you are always on my mind, and I will always
treasure all my shared moments. It is cliché to say but I am who I am right now because
of you, and you will always be a part of me. I hope one day I will get to see and spend
time with each and every one of you. In the meantime, I wish all of you all a joyous
journey.

iv

ABSTRACT

REGULATION OF THE TUBULIN CODE IN CARDIAC HYPERTROPHY AND FAILURE
Sai Aung Phyo
Benjamin L. Prosser

A proliferated and post-translationally modified microtubule network underlies
cellular growth in cardiac hypertrophy and contributes to contractile dysfunction in heart
failure. Yet how the heart achieves this modified network is poorly understood.
Determining how the “tubulin code” – the permutations of tubulin isoforms and posttranslational modifications – is rewritten upon cardiac stress may provide new targets to
modulate cardiac remodeling. Further, while tubulin can autoregulate its own expression,
it is unknown if autoregulation is operant in the heart or tuned in response to stress.
Here I use heart failure patient samples and murine models of cardiac remodeling to
interrogate transcriptional, autoregulatory, and post-translational mechanisms that
contribute to microtubule network remodeling at different stages of heart disease. I find
that autoregulation is operant across tubulin isoforms in the heart and leads to an
apparent disconnect in tubulin mRNA and protein levels in heart failure. I also find that
within 4 hours of a hypertrophic stimulus and prior to cardiac growth, microtubule
detyrosination is rapidly induced to help stabilize the network. This occurs concomitant
with rapid transcriptional and autoregulatory activation of specific tubulin isoforms and
microtubule motors. Upon continued hypertrophic stimulation, there is an increase in
post-translationally modified microtubule tracks and anterograde motors to support
cardiac growth, while total tubulin content increases through progressive transcriptional
and autoregulatory induction of tubulin isoforms. My work provides a new model for how
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the tubulin code is rapidly rewritten to establish a proliferated, stable microtubule
network that drives cardiac remodeling, and provides the first evidence of tunable tubulin
autoregulation during pathological progression.
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CHAPTER 1: INTRODUCTION
A. The heart and its functional subunit, the cardiomyocytes
The heart, a muscular organ that resides in the thorax of vertebrates, sits at the
core of the circulatory system and is responsible for the circulation of blood throughout
an organism. In human, the heart is divided into 4 chambers, namely: 1) right-atrium, 2)
right-ventricle, 3) left-atrium, and 4) left-ventricle. The right and left atria receive blood
from the systemic or the pulmonary circulation, whereas the right and left ventricles
pump blood into the pulmonary or the systemic circulation, respectively. Since the leftventricle is responsible for pumping blood throughout the body, it is this chamber that
encounters the highest resistance (afterload) and produces the strongest force to
overcome the resistance.
The pumping action of the heart is achieved by the collective and synchronized
contraction of the cardiomyocytes, the functional subunit of the heart. In addition to the
cardiomyocytes, which accounts for ~56% of the cells (Banerjee et al., 2007) or ~7085% of the volume (Zhou and Pu, 2016) in the heart, the heart also consists of other cell
types such as cardiac fibroblast, vascular smooth muscles, and immune cells such as
macrophages(Pinto et al., 2016). All these cells are indispensable for the structure and
function of the heart, but cardiomyocytes are the main source of force generation. Within
a cardiomyocyte, the basic contractile unit known as a sarcomere, which is mainly
composed of actin and myosin proteins, is responsible for force generation through
shortening from its normal resting length of ~2.2µm in cardiomyocytes(Pollack and
Huntsman, 1974).
Cardiomyocytes are terminally differentiated cells and are responsive to electrical
stimulation. At the molecular level, the contraction of cardiomyocyte is initiated by the
1

depolarization of the sarcolemma that travels down the T-tubules and leads to an influx
of extracellular calcium through the L-type calcium channels(Tanabe et al., 1990). This
influx of calcium triggers rapid release of sarcoplasmic-reticulum (SR) -stored calcium
into the cytosol via the type 2 ryanodine receptor (RyR2) at the junctional-SR through a
process commonly known as calcium-induced calcium release (CIRC)(Ferrier and
Howlett, 2001). This rise in cytosolic calcium concentration enables myosin binding to
actin that leads to the shortening of sarcomeres and thus produces a contractile force.
Following the calcium-induced contraction, the cardiomyocyte must also relax
adequately to allow the chambers to be filled with blood properly for subsequent
ejection. Additionally, the cardiomyocyte stretch induced by the forces of the filling blood
(preload) allows proper contraction through the Frank-Starling mechanism(Frank, 1959).
During the relaxation phase, SR rapidly reuptake calcium through the sarco/endoplasmic
reticulum calcium-ATPase (SERCA)(Brini and Carafoli, 2009), leading to a fall in
cytosolic calcium concentration and subsequent dissociation of myosin from actin. This
leads to lengthening of the cardiomyocyte back to its resting length, primed for a
subsequent contraction.
Given the central importance of calcium signaling in the heart, it is through this
modulation of calcium signaling by which the heart achieves short-term variations in the
strength of contraction (reviewed in:(Eisner et al., 2017). However, when the heart needs
to produce stronger force of contraction for an extended period due to physiological or
pathological increases in afterload or preload, regulation solely through calcium signaling
becomes unsustainable. To overcome this problem, the heart needs to increase the total
number of sarcomeres that can ultimately increase the ability of the heart to generate
greater force. This could be accomplished by either increasing the number of
cardiomyocytes through cell division and thus effectively increases the number of
2

sarcomeres, or by the addition of new sarcomeres to those preexisting in
cardiomyocytes. Since cardiomyocytes are terminally differentiated and are no longer
capable of cellular division, the only way feasible is for the cardiomyocytes to grow larger
through the process of cardiac hypertrophy.

B. Pathological cardiac hypertrophy and heart failure
The initial onset of hypertrophy is an adaptive response to increase contractility
to match the increased demand. The newly synthesized sarcomeres are added to the
pre-existing sarcomeres either in parallel leading to thicker walls and a smaller chamber
known as concentric hypertrophy, or in series leading to thinner walls and a bigger
chamber known as eccentric hypertrophy. The precise molecular determinants that
control concentric versus eccentric hypertrophy are yet to be identified. However, it has
been established that the heart undergoes concentric or eccentric hypertrophy in
response to increased afterload such as pressure-overload or to increased preload such
as fluid-overload, respectively(Gaasch, 1979). Although most causes of pathological
cardiac hypertrophy are in response to increased afterload or preload, there are also
genetic causes that leads to cardiac hypertrophy, such as a frameshift mutation of
MYBPC3 gene that encodes for cardiac myosin binding protein C (cMyBP-C)(Carrier et
al., 1997).
Regardless of the etiology of pathological remodeling, as long as the heart with
its increased sarcomere numbers can meet the increased demand of an organism, the
hypertrophy is said to be compensated. However, since pathological hypertrophy is
associated with the activation of natriuretic peptides (Rockman et al., 1991) and
reactivation of many fetal genes such as the expression of myosin heavy chain 7
(MYH7)(Morkin, 1993) as well as fibrosis and some cardiac dysfunctions (Weeks et al.,
3

2017) overtime this compensated hypertrophy can become decompensated which is
when the heart can no longer supply the necessary demand; this decompensation is
accompanied by further processes such as cardiomyocyte apoptosis, calcium
dysregulation, and metabolic reprogramming (reviewed in:(Nakamura and Sadoshima,
2018). Moreover symptoms of heart failure first emerge during this maladaptive
decompensation.
Heart Failure is a complex condition in which the patient presents with symptoms
such as fatigue and shortness of breath, as a sequela of mismatched supply and
demand of cardiac output. The mismatch can stem from diastolic dysfunction, in which
the thickened walls fail to relax adequately during the filling of blood, or systolic
dysfunction, in which the thinned walls fail to contract adequately to force blood out.
Current heart failure therapies include the use of inotropes to increase contractility for
systolic dysfunction(Tariq and Aronow, 2015) or diuretics to decrease fluid overload for
diastolic dysfunction(Ha and Oh, 2009). These therapies can decelerate the progression
of heart failure, but it would better if we can prevent decompensation in the first place.
Although the progression of cardiac hypertrophy to heart failure seems like a
one-way direction, reversal of cardiac hypertrophy is feasible and has been observed.
For example, using dilated cardiomyopathy (DCM) mice model, McMullen et al. showed
that DCM mice subjected to swim training live longer than the untrained controls and
showed lower levels of fetal gene transcription (McMullen et al., 2007). Likewise, obese
and sedentary patients with left-ventricular hypertrophy can reverse and induce
favorable changes in their left-ventricular structure, assessed through echocardiography,
by weight management and aerobic exercise(Hinderliter et al., 2002). Hence, if we were
to fully understand the temporal progression of the pathological changes during cardiac
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hypertrophy, we could find points of intervention to reverse cardiac hypertrophy and thus
prevents its progression to heart failure.
With regards to future interventions for heart failure, recent research into the
pathophysiology of heart failure has yielded great insights that could one day translate
into even more effective therapies and treatments. For example, metabolomic study
using blood from artery, coronary sinus, and femoral vein from normal and heart failure
patients shows that failing heart preferentially uses ketones and lactate instead of fatty
acids(Murashige et al., 2020). Though the complete mechanism of such switch in
metabolite remains to be elucidated, thorough characterizations of the different
pathological changes associated with cardiac hypertrophy and failure would inevitably
open new avenues for treatment of heart diseases.
A rapidly evolving area of cardiac research is studying the role of microtubules in
heart diseases such as hypertrophy and heart failure. Microtubules have been shown to
be essential for the development of cardiac hypertrophy(Fassett et al., 2019, 2009;
Scarborough et al., 2021), and contribute to contractile dysfunction in heart
failure(Caporizzo et al., 2018, 2020; Chen et al., 2018; Tsutsui et al., 1999). I will expand
on the role of microtubules in heart disease in more details below.

C. The biology of microtubules and the tubulin code
Microtubules are hollow tubular structures found inside all eukaryotic cells. They
are about 25nm in diameter, consisting of 13 laterally associated protofilaments(Sui and
Downing, 2010), and are formed through the guanosine-5’-triphosphate (GTP)
dependent polymerization of obligate heterodimers of a- and b- tubulin(Weisenberg et
al., 1976). They play essential roles in the structural support of cells, intracellular
transport, cell motility, and mitosis(Inoué and Sato, 1967; Nogales, 2001). Unlike other
5

cytoskeletal elements, microtubules exist in a dynamic state whereby they exhibit
periods of stochastic growth and shrinkage(Mitchison and Kirschner, 1984). In addition
to growth and shrinkage, microtubules undergo catastrophe, during which a microtubule
quickly depolymerizes from the “plus-end” to form free tubulin dimers, and rescue, during
which the catastrophic event is halted to resume growth. Despite the dynamicity of the
microtubules, during normal physiological conditions, the free and polymerized tubulin
pools exist in a state of equilibrium and the total mass of both a- and b- tubulin is kept
relatively constant.
In addition to transcriptional regulation of tubulin genes to keep a constant level
of tubulin transcripts in a cell at a given time(Havercroft and Cleveland, 1984), the
abundance of tubulin transcript is also controlled through a tubulin-specific mRNA
regulatory mechanism known as autoregulation(Ben-Ze’ev et al., 1979; Cleveland et al.,
1983). Autoregulation is controlled by the relative free : polymerized tubulin
concentration in the cell(Ben-Ze’ev et al., 1979; Cleveland et al., 1981). When free
tubulin level increases, such as during the depolymerization of microtubules by
depolymerizing agents such as colchicine, the free tubulin dimers activate a ribosomal
RNase to degrade nascent tubulin transcripts (autoinhibition) that have been docked on
ribosome for translation; conversely, when free tubulin level decreases, autoregulation is
released (autoactivation) allowing the nascent transcripts to be to restore a homeostatic
concentration of free tubulin with respect to the total microtubules. The complete
mechanism by which the free tubulin triggers the activation of ribosomal RNase is
unknown but through mutagenesis of the b-tubulin, it is known that the Met-Arg-Glu-Ile
(MREI) motif that resides close to the N-terminus is necessary and sufficient for
autoregulation(Yen et al., 1988).

6

Since the discovery of autoregulation in 1979 by Ben-Ze’ev & colleagues, the
field of autoregulation has been static despite its importance in tubulin biology. In the
past two years, increasing number of research has been undertaken to further my
understanding of autoregulation. Lin et al. in 2020 showed that the protein
Tetratricopeptide repeat domain 5 (TTC5) plays an indispensable role in autoregulation
by allowing the MREI motif on the nascent tubulin peptide to be recognized by the
ribosome to activate RNase for transcript degradation(Lin et al., 2020). Additionally,
autoregulation was generally thought of as a degradation mechanism that degrades
mRNA in the presence of excess free tubulin; then in 2019, Gasic et al. showed that
autoregulation can also increase the level of mature tubulin RNA without a
corresponding increase in nascent tubulin transcript (Gasic et al., 2019). These research
opens an interesting line of questioning on the interplays of transcription and
autoregulation in the temporal control of tubulin transcripts and proteins in different
physiological and pathological conditions.
Autoregulation becomes more intriguing when given the fact that there are a
multitude of a and b -tubulin isoforms that arise not from alternative gene splicing but
from different tubulin genes and serve different purposes (reviewed in:(Janke and
Magiera, 2020). In humans, there are nine a- and nine b- tubulin isoforms, whereas in
mice, there are seven a- and eight b- tubulin isoforms. Despite some homologies
between the tubulin isoforms, study using Drosophila melanogaster b- tubulin isoforms
shows that the tubulin isoforms are non-redundant and that they have different intrinsic
functional capacity(Hoyle and Raff, 1990). Interestingly, using in vitro cancer cell lines,
autoregulation was observed to regulate tubulin on an isoform-specific level (Gasic et al.,
2019). Despite its relevance in tubulin biology, tubulin isoforms and autoregulation of
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cardiac microtubules remains underappreciated, and their roles in cardiac physiology
and pathological remains unexplored.
In addition to the diverse array of tubulin isoforms, the tubulin subunits are also
subjected to diverse post-translational modifications (PTMs) such as detyrosination and
acetylation. Microtubule PTMs have been shown to influence microtubule stability and
dynamics as well as their biochemical properties. The permutation of the ab-tubulin
isoforms and their PTMs is known as the “tubulin code” (Figure 1) and this cell-type and
context-dependent tubulin code results in microtubule networks with distinct biochemical
and mechanical properties.
Finally, in addition to the tubulin code, the property and complexity of
microtubules are further diversified by microtubule-associated proteins (MAPs) and
motors, whose interactions with microtubules are also regulated by the tubulin code.
MAPs themselves can be post-translationally modified, are expressed in a cell-type and
context-dependent fashion and can impart further biophysical properties when
associated with microtubules (Janke and Magiera, 2020).

D. Microtubules in the heart and heart diseases
While cardiac microtubules are indispensable for cardiomyocyte’s cellular
processes such as intracellular transport, microtubules serve additional functions in the
heart. Microtubules, which were conventionally thought of as stiff cytoskeletal rods that
runs the length of the cardiomyocyte(McGrath, 2006), were shown to be indeed flexible
structures that contribute dynamically during both contraction and relaxation of the
cardiomyocyte(Brangwynne et al., 2006; Robison et al., 2016). Through its interactions
with an intermediate filament in the cardiac Z-disk structure, desmin, microtubules were
directly observed to buckle during cardiac contraction. Owing to the viscoelastic
8

properties of the microtubule network, subsequent study shows the buckling and
unbuckling of microtubules add resistance during both the contractile and relaxation
phases(Caporizzo et al., 2018).
In addition, microtubules are also involved in the structural integrity of the
nucleus inside the cardiomyocyte(Heffler et al., 2020). In addition to the pulling force
exerted on the nucleus by desmin intermediate filaments, microtubules exert a pushing
force on the nucleus, keeping a balance of forces to maintain a homeostatic nuclear
shape. The interaction between desmin and microtubules to the nuclear membrane is
mediated by KASH-domain containing nesprin proteins in the outer nuclear membrane
and SUN-domain containing inner nuclear membrane proteins(Tapley and Starr, 2013).
Thus, through microtubules and desmin, the nucleus is physically coupled to the cell
membrane and allows the transduction of mechanical stimuli from the cell periphery to
the nucleus.
During cardiac hypertrophy and heart failure, the microtubule network is
significantly remodeled and acts as a double-edged sword. On one hand, a proliferated,
stable microtubule network is essential for the development of cardiac hypertrophy in
response to stressors such as adrenergic stimulation and hemodynamic
overload(Fassett et al., 2019, 2009; Sato et al., 1997; Scarborough et al., 2021). Upon
such hypertrophic stimuli, a dense microtubule network and the anterograde motor
protein kinesin-1 coordinates the trafficking of mRNA and the translational machinery to
control local synthesis and integration of nascent proteins(Scarborough et al., 2021). In
the absence of microtubules, increased protein translation is decoupled from protein
integration and the heart fails to grow(Scarborough et al., 2021), identifying an essential
role of microtubule-based transport in adaptive cardiac growth.
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On the other hand, a collective body of research has also established a causal
link between aberrant microtubule remodeling, the tubulin code, and impaired cardiac
mechanics in heart failure(Caporizzo et al., 2019; Magiera et al., 2018; Tsutsui et al.,
1999). In the hearts of heart failure patients(Chen et al., 2018) and pressure-overloaded
animals(Fassett et al., 2019; Sato et al., 1997), microtubule density is consistently
increased, and its pharmacological dedensification partially restores dysfunctional
cardiac contractility(Caporizzo et al., 2018; Tsutsui et al., 1999).
Moreover, detyrosination, a PTM of a-tubulin, is increased in the myocardium of
pressure-overload animals(Fassett et al., 2019; Sato et al., 1997), and in the
cardiomyocytes(Chen et al., 2018) and myocardium(Schuldt et al., 2020) of heart failure
patients. Detyrosination is the removal of the penultimate tyrosine residue on the Cterminal tail of polymerized a-tubulin by vasohibins 1 & 2 (VASH1/2)(Aillaud et al., 2017;
Nieuwenhuis et al., 2017); tubulin tyrosine ligase (TTL) mediates the reverse
reaction(Szyk et al., 2011). Mechanistic studies into microtubule detyrosination identified
it as a critical determinant of myocyte mechanics(Robison et al., 2016), whereby
detyrosinated microtubules impart a viscoelastic drag that limits cardiomyocyte motion
during the cardiac cycle(Caporizzo et al., 2020). Suppressing detyrosination in failing
cardiomyocytes using parthenolide (Chen et al., 2018), TTL overexpression(Chen et al.,
2018), or VASH1 depletion(Chen et al., 2020) lowers cardiomyocyte stiffness and
ameliorates the dysfunctional contractility.
A recent study reported a novel axis involving rapid microtubule detyrosination
and microtubule-affinity regulating kinase 4 (MARK4) during cardiac ischemia(Yu et al.,
2021). The authors demonstrated that MARK4-induced MAP4 phosphorylation
dissociates MAP4 from polymerized microtubule, giving VASH2 access to detyrosinated
microtubules(Yu et al., 2021). Despite these advances, the temporal progression of
10

detyrosination, particularly in the context of non-ischemic cardiac remodeling, remains
unclear.
Acetylation of a-tubulin has also been recently examined in the heart. Acetylation
is an addition of an acetyl group on K40 of polymerized a-tubulin by a-Tubulin
acetyltransferase 1 (aTAT1)(Kalebic et al., 2013); deacetylation is mediated by histone
deacetylase 6 (HDAC6)(Hubbert et al., 2002). Acetylated microtubules are resilient
against repeated mechanical stresses(Portran et al., 2017) and resistant to mechanical
breakage(Xu et al., 2017). Acetylation is induced in hypertrophic cardiomyopathy(Dorsch
et al., 2019); however, the mechanical consequences of this induction remain unclear,
as different studies in various contexts have seen both softening(Swiatlowska et al.,
2020) and stiffening(Coleman et al., 2021) effects of acetylation on the cardiomyocyte.
While more work is needed, these studies add to a growing body of literature indicating
diverse regulation and functional consequences of ab-tubulin PTMs in cardiac
physiology and pathology.
In addition to the tubulin code, several MAPs are also implicated in cardiac
remodeling. MAP4, the most abundant cardiac MAP, binds and stabilizes microtubules
in a phosphorylation-dependent manner. MAP4 is increased in human heart failure(Chen
et al., 2018) and in feline pressure-overload induced cardiac hypertrophy(Sato et al.,
1997), and MAP4 dephosphorylation at S924 and S1056 has been causally linked to
microtubule network stabilization and densification(Chinnakkannu et al., 2010).
Conversely, Li et al. demonstrated that MAP4 hyperphosphorylation at S737 and S760 is
also sufficient to drive eccentric remodeling in mice(Li et al., 2018).
Similar to MAP4, phosphorylation of CLIP170 (CAP-Gly Domain Containing
Linker Protein 1/170), a microtubule plus-end tracking protein, by AMP-activated protein
kinase (AMPK) leads to its dissociation from microtubule plus-ends and de-stabilizes
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microtubules(Nakano et al., 2010). Yashirogi et al. recently demonstrated that in the
absence of mechanical-stress dependent localization of AMPK to the cardiac
intercalated disks to phosphorylates and dissociates CLIP170 from microtubules,
microtubules accumulate at the intercalated disk causing eccentric hypertrophy with
reduced ejection fraction(Yashirogi et al., 2021). Hence, through such changes in the
tubulin code and the associated MAPs, microtubules play an indispensable role in heart
disease.
While the state of the microtubule network in advanced heart failure has been
well-defined by recent studies(Chen et al., 2018; Schuldt et al., 2020), we know little
about the drivers and temporal progression of changes to the microtubule network that
occur during the early phases of cardiac remodeling such as during cardiac hypertrophy.
There are a multitude of mechanisms to achieve a dense, heavily post-translationally
modified microtubule network as observed in cardiac hypertrophy and heart failure. A
seemingly obvious mechanism to increase tubulin mass is through transcriptional
upregulation; yet when I examine published transcriptomic and proteomic data from
heart failure samples, we observe a consistent inverse correlation between tubulin
mRNA and protein levels across different causes of heart failure in multiple studies (Fig.
2A-B). This motivates a deeper examination between transcriptional and translation
coupling of ab-tubulin isoforms and other factors that could contribute to microtubule
proliferation.
In this study, I aimed to comprehensively characterize the time-dependent
changes to the tubulin code and MAPs during the early stages of cardiac microtubule
remodeling at the network, protein, and transcript levels. Additionally, given the central
importance of autoregulation in tubulin biology, and as no studies have been undertaken
to determine its role in cardiac pathophysiology, I sought to elucidate how tubulin
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autoregulation affects microtubule synthesis during cardiac hypertrophy. To this end, I
combined two acute models of adrenergic stress-induced cardiac hypertrophy with
echocardiographic, histologic, transcriptomic, and proteomic assessments to gain insight
into cytoskeletal remodeling during the transition from a non-pathological state to cardiac
hypertrophy. my goal is to provide a comprehensive assessment of this process to open
novel lines of inquiry into cardiac hypertrophy and provide new targets for the reversal or
prevention of hypertrophy and its progression into heart failure.
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CHAPTER 2: METHODS AND MATERIALS
A. Human myocardial tissue
Procurement of human myocardial tissue was performed under protocols and
ethical regulations approved by Institutional Review Boards at the University of
Pennsylvania and the Gift-of-Life Donor Program (Pennsylvania, USA) and as
described(Chen et al., 2018). In summary, failing human hearts were procured at the
time of orthotropic heart transplantation at the Hospital of the University of Pennsylvania
following informed consent from all participants. Non-failing hearts were obtained at the
time of organ donation from cadaveric donors. In all cases, hearts were arrested in situ
using ice-cold cardioplegia solution and transported on wet ice. Transmural myocardial
samples were dissected from the mid left ventricular free wall below the papillary muscle
and the samples were kept frozen at 80°C. Contractile parameters, including left
ventricle ejection fraction, were determined by echocardiography in subjects. In this
study, a total of 35 donor hearts were used. 12 donors were classified as near-normal
non-failing (NF) without left-ventricular hypertrophy, and 23 donors were classified as
heart failure with 12 hearts from hypertrophic cardiomyopathy patients and 11 hearts
from dilated cardiomyopathy patients.

B. Animal care
Animal care and procedures were approved and performed in accordance with
the standards set forth by the University of Pennsylvania Institutional Animal Care and
Use Committee (IACUC) and the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH).
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C. Drug injection
Eight to twelve weeks old male C57/Bl6 mice were used throughout the study.
On days 0 and 2, based on their body weights, mice were subcutaneously injected with
either ascorbic acid (Ctrl, Sigma-Aldrich: A92902), 10mg/kg phenylephrine (PE, SigmaAldrich: P6126) prepared in Ctrl, or 5mg/kg isoproterenol (Iso, Sigma-Aldrich: I6504)
prepared in Ctrl.

D. Cardiac Tissue Harvest
Mice were put under general anesthesia using isoflurane and the hearts were
surgically removed. Excised hearts were thoroughly washed in ice-cooled PBS and
extra-cardiac tissues were removed. To properly measure heart weight (HW), residual
blood from the chambers was removed by sandwiching the heart between Kimwipes and
gently squeezing it. After HW measurement, atrial and right ventricular tissues were
removed, the remaining septal and left-ventricular tissues were cut into five pieces of
similar size and from similar locations of the heart. The weights of the individual pieces
were recorded, frozen in liquid nitrogen, and stored at -80°C until further processing.
Concurrent with tissue harvest, the tibia length (TL) of respective mouse was measured
to calculate HW-over-TL (HW/TL).

E. Exclusion criteria
During the study: for the 4-hour time point, there were 6 mice per treatment
group for a total of 18 mice, and for the 4-day time point, there were 8 mice per
treatment group for a total of 24 mice. As I aimed to study mice who underwent
consistent cardiac hypertrophy, for the 4-day time point, I set exclusion criteria as the
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followings: (1) hearts whose HW/TL were beyond 2 standard-deviations (SD) of the
population mean, and (2) experimental hearts whose classical hypertrophy response
genes were not changed relative to that of the control hearts. After the removal of
outliers, in the final study: for the 4-hour time point, there are 6 mice per treatment group
for a total of 18 mice, and for the 4-day time point, there are 7 mice in Ctrl, 7 mice in PE,
and 6 mice in Iso, for a total of 20 mice.

F. Mouse cardiomyocyte isolation, culture, and drug treatment
Primary adult ventricular myocytes were isolated from 8- to 12-week-old C57/Bl6
mice using the protocol previously described(Prosser et al., 2011). Briefly, mice were put
under general anesthesia using isoflurane and were injected peritoneally with heparin
(~1000 units/kg). The heart was excised and cannulated to a Langendorff apparatus for
retrograde perfusion with enzymatic digestion solution at 37°C. Once digested, the heart
was minced and triturated with glass pipettes. The isolated cardiomyocytes were
centrifuged at 300 revolution per minute for 2 minutes. The supernatant containing
debris was discarded and the isolated cells were resuspended in cardiomyocyte media
containing Medium 199 (GIBCO: 11150-59) supplemented with 1x insulin-transferrinselenium-X (GIBCO: 51500-56), 20mM HEPES pH 7.4, 0.1 mg/mL Primocin, and 25
mmol/L of cytochalasin D. Immediately following cell isolation, the cardiomyocytes were
treated with either DMSO, 10mM colchicine, or 10mM taxol, and incubated at 37°C and
5% CO2 for 6 hours.

16

G. Echocardiography
On day 4, transthoracic echocardiography was performed on mice, which were
anesthetized using intraperitoneal injection of 0.01mL/gram body weight of 2.5% Avertin,
using Vevo2100 Ultrasound System (VisualSonics Inc., Toronto, Ontario, Canada).
Fractional shortening, chamber dimensions, and ventricular wall-thickness were
measured from short axis M-mode images at the mid-level view of the papillary muscle.

H. Total protein lysate preparation
Frozen aliquoted cardiac tissue obtained from similar locations of the heart was
pulverized finely using a liquid nitrogen-cooled mortar and pestle. 1x
Radioimmunoprecipitation assay (RIPA) buffer (Cayman Chemical Company: 10010263)
supplemented with 1x protease inhibitor cocktail (Cell Signaling Technology: 5872S) and
1:200 diluted endonuclease (Lucigen: OC7850K) was immediately added to the
pulverized tissue at a constant ratio of 15µL/mg of tissue. The sample was then
mechanically homogenized using a handheld homogenizer until visible chunks of tissues
were dissociated. The sample was incubated for 10 minutes on ice to allow
endonuclease to cleave DNA. After processing of all samples, the samples underwent
two freeze-thaw cycles, after which, equal-volume of 5% SDS-10% glycerol boiling
(SGB) buffer was added to each sample. The samples were vortexed thoroughly then
heated to 100°C for 8 minutes. Residual undissolved cell debris were removed from the
resulting samples by centrifugation at 8000g for 5 minutes at room temperature (22°C).
The concentrations of the total protein were determined using Bicinchoninic acid (BCA)
assay; all samples were diluted to 4µg/µL using RIPA:SGB buffer. The diluted total
protein lysates were aliquoted and stored at -80°C until further processing.
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I.

Microtubule Fractionation
100mM PIPES-KOH pH 6.8, 1mM MgCl2, 1mM EGTA-KOH pH 7.7 (PME) buffer

was prepared fresh and was supplemented with 1mM DTT, 1mM GTP (Sigma-Aldrich:
G8877), and 1x protease inhibitor cocktail. 7 parts supplemented PME buffer was mixed
with 3 parts glycerol; the final PME-30G buffer was kept incubated in a 37°C water bath.
Frozen aliquoted cardiac tissue obtained from similar locations of the heart was
pulverized crudely using a liquid nitrogen-cooled mortar and pestle. Immediately
following pulverization, warmed PME-30G buffer was added at a constant ratio of
20µL/mg of tissue. The sample was then mechanically homogenized using the handheld
homogenizer until visible chunks of tissues were dissociated and was set aside at 22°C
until all samples were processed.
All processed samples were then centrifuged at 16000g for 15 minutes at 30°C;
the supernatants were transferred into fresh tubes and were saved as free tubulin (Free)
fractions. 10µL of 1 part RIPA and 1 part SGB (RIPA:SGB) buffer was added to the
pellet obtained from 1mg of tissue and the sample was homogenized using the handheld
homogenizer. After processing of all samples, the samples were heated to 100°C for 8
minutes, cooled on ice, and centrifuged at 8000g for 5 minutes at 22°C; the supernatants
were transferred into fresh tubes and were saved as polymerized tubulin (Poly) fractions.
The concentrations of the Poly fractions were determined using BCA assay. The Poly
fractions were diluted to 4µg/µL using RIPA:SGB buffer; the respective Free fraction was
diluted with PME-30G buffer using twice the volume needed to dilute the Poly fraction.
The final diluted Free and Poly fractions were aliquoted and stored at -80°C until further
processing.
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J. Sample preparations and Western blot (WB) analysis
To quantify the relative abundance of specific proteins of interest in the total
protein lysate, aliquoted diluted total protein lysate samples were thawed at 22°C. 1 part
4x loading buffer (125mM Tris-HCl pH 6.8, 35% v/v glycerol, 0.2% w/v Orange G) freshly
supplemented with 10% v/v b-mercepthoethanol (BME) was mixed with 3 parts total
protein lysate to get final concentrations of 1x loading buffer with 2.5% BME, and 3µg/µL
of total protein. The final samples were heated to 100°C for 8 minutes. The heated
samples were cooled to 22°C, centrifuged briefly, vortexed thoroughly, and loaded
5µL/sample onto precast protein gels (Bio-Rad: 5671085).
To quantify the relative abundances of the Free and Poly fractions, aliquoted
diluted Free and Poly fractions were thawed at 22°C. For the Free fractions, 2x loading
buffer (62.5mM Tris-HCL pH 6.8, 5% v/v SDS, 0% glycerol, 0.1% w/v Orange G) freshly
supplemented with 5% v/v BME was used, whereas, for the Poly fractions, 4x loading
buffer freshly supplemented with 10% v/v BME was used; to prepare the final samples,
the respective loading buffers were diluted to 1x using the Free and Poly fractions. The
final samples were heated to 100°C for 8 minutes. The heated samples were cooled to
22°C, centrifuged briefly, vortexed thoroughly, and loaded 5µL/Poly fraction and
10µL/Free fraction onto precast protein gels.
Protein gel electrophoresis was carried out under constant voltage of 135V for
the Midi gels for 1 hour. The resolved proteins were transferred onto a nitrocellulose
membrane using the Turbo Transfer System (Bio-Rad) under recommended conditions.
The post-transferred membrane was blocked in blocking buffer (LI-COR Biosciences:
927-60003) for at least 1 hour at 22°C (or overnight at 4°C). The blocked membrane was
incubated overnight at 4°C with primary antibodies diluted in 1x Tris buffered saline with
Tween-20 (TBST, Cell Signaling Technology: 9997S). The membrane was washed twice
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using TBST and incubated for 1 hour at 22°C with secondary antibodies diluted in
blocking buffer. The final immunoblotted membrane was washed twice using TBST and
was imaged using the Odyssey Western Blot Imaging System (LI-COR Biosciences).

K. WB data analysis
The WB data was analyzed using Image Studio Lite (LI-COR Biosciences). The
signal intensity of an individual band was obtained by drawing a rectangular block
encompassing the entire band. The background was thresholded using the parameters:
median, border width = 3, Top/Bottom. 2 technical replicates (n) per sample, and 6
biological replicates (N) per treatment for 4-hour time point and 8 biological replicates
per treatment for 5-day time point were used in the analysis. GAPDH intensity was used
as a loading control. A mean value of the Ctrls that were run on the same blot was used
to normalize the data and to calculate the relative fold-changes over the Ctrl. Statistical
analyses were performed as described below.

L. Mass spectrometry (MS) sample preparation
To quantify the relative changes of multiple proteins of interest in the total protein
lysate, aliquoted diluted total protein lysate samples were thawed at 22°C. 1 part 4x
loading buffer freshly supplemented with 10% v/v BME was mixed with 3 parts total
protein lysate. The final samples were heated to 100°C for 8 minutes. The heated
samples were cooled to 22°C, centrifuged briefly, vortexed thoroughly, and loaded
50µL/sample onto precast protein gels (Bio-Rad: 4561034). Protein gel electrophoresis
was carried out under constant voltage of 110V for the Mini gels for 1.5 hours. The
resolved protein gel was stained with Coomassie blue (Bio-Rad: 1610435) using the
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provided protocol. After the destaining of the gel, the 50kDa bands were carefully
excised and stored in deionized water at 4°C until further processing.
The gel bands were destained with 100mM ammonium bicarbonate/acetonitrile
(50:50). The bands were reduced in 10mM dithiothreitol/100mM Ammonium bicarbonate
for over 60 minutes at 52°C; the bands were then alkylated with 50mM
iodoacetamide/100mM ammonium bicarbonate at 22°C for 1 hour in the dark. The
proteins in the gel bands were digested with enzymes while incubating overnight at
37°C; different enzymes such as trypsin, Chymotrypsin, and Glu-C were used according
to protein sequences. The supernatants were transferred and kept in fresh tubes.
Additional peptides were extracted from the gel by adding 50% acetonitrile/1% TFA and
incubated for 10 minutes on a shaker. The supernatants were combined and dried. The
dried samples were reconstituted using 0.1% formic acid for MS analysis.

M. MS analysis using Nano-LC-MS/MS
Peptides were analyzed on a Q-Exactive HF (Thermo Fisher Scientific) attached
to an Ultimate 3000 rslcnano system (Thermo Fisher Scientific) at 400 nL/min. Peptides
were eluted with a 55 minutes gradient from 5% to 32% ACN (25 minutes) and 90%
ACN over 5 minutes in 0.1% formic acid. Data-dependent acquisition mode with a
dynamic exclusion of 45 seconds was enabled. One full MS scan was collected with a
scan range of 350 to 1200 m/z, resolution of 70 K, maximum injection time of 50
milliseconds, and AGC of 1 x 106. Then, a series of MS2 scans were acquired for the
most abundant ions from the MS1 scan (top 12). Ions were filtered with charges 2–4. An
isolation window of 2 m/z was used with quadruple isolation mode. Ions were
fragmented using higher-energy collisional dissociation (HCD) with a collision energy of
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27%. Orbitrap detection was used with a scan range of 140 to 2000 m/z, resolution of 30
K, maximum injection time of 54 milliseconds, and AGC of 50,000.

N. MS data analysis
Proteome Discoverer (Thermo Fisher Scientific, version 2.4) was used to process
the raw spectra. Default search parameters were used, including precursor mass
tolerance of 10 ppm, fragment mass tolerance of 0.02 Da, enzymes specific cleavage,
and up to 2 mis-cleavage. Carbamidomethyl [C] was set as a fixed modification, while
Oxidation [M] and Acetylation [N-terminal and K] were set as variable modifications. The
target-decoy approach was used to filter the search results, in which the false discovery
rate was less than 1% at the peptide and protein levels. For measuring the relative
protein abundances, all the chromatographic data were aligned and normalized to
peptide groups and protein abundances, missing values were imputed and scaled. The
normalized protein abundance values from 4 Ctrls, 5 PE, and 4 Iso 4-day mice were
used in the subsequent analysis. Since the different tubulin isoforms share multiple
homologous regions, only unique peptides that are unambiguous to each isoform were
used to calculate protein abundance. The unique peptides acquired for the analyzed
isoforms ranged from 1-13 peptides and the full suite of peptide and protein groups used
in the analysis can be found in the public proteomic repository as outlined in the data
availability statement. Statistical analyses were performed on the calculated protein
abundances as described below.
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O. Total RNA extraction
Frozen aliquoted cardiac tissue obtained from similar locations of the heart was
pulverized finely using a liquid nitrogen-cooled mortar and pestle. 500µL of ice cooled
RNAzol (Molecular Research Center: RN 190) was added to the pulverized tissue and
immediately homogenized using the handheld homogenizer until visible chunks of
tissues were dissociated. 200µL of molecular grade water was added to the sample; the
sample was vortexed and incubated for 15 minutes at 22°C. After processing of all
samples, the samples were then centrifuged at 12000g for 15 minutes at 22°C. 550µL of
the clear supernatant was carefully removed and transferred into a fresh tube. 550µL of
isopropanol was then added to the supernatant, vortexed, and incubated for 10 minutes
at 22°C. The samples were centrifuged at 16000g for 10 minutes at 22°C, and the
resulting supernatants were discarded. The visible RNA pellets were washed in 75%
ethanol in molecular grade water three times. The undried RNA pellets were
resuspended in 30µL of RNase free water. The total RNA concentrations, and 260/230
and 260/280 ratios were determined using NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies). The RNA samples were stored at -80°C until further analysis.

P. NanoString nCounter analysis
Total RNAs from 37 samples were analyzed. The concentration of the total RNA
was reassessed using NanoDrop spectrophotometer. The quality of the total RNA was
assessed using the Agilent 4200 TapeStation (Agilent Technologies). Only samples that
were pure as defined by OD 260/280 and 260/230 ratios > 1.8, and integrity RIN value >
8.0 were used in the study. 100ng of total RNA per sample for tubulin and hypertrophy
panels or 200ng of total RNA per sample for tubulin autoregulation panel was used for
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the subsequent step. Hybridization between the target mRNA and reporter-capture
probe pairs was performed for 18 hours at 65°C using Mastercycler Pro S Thermal
Cycler (Eppendorf) according to the manufacturer’s protocol. Post-hybridization
processing was carried out on a fully automated nCounter Prep Station (NanoString
Technologies) liquid-handling robotic device using the High Sensitivity setting. For image
acquisition and data processing, the probe/target complexes were immobilized on the
nCounter cartridge that was then placed in the nCounter Digital Analyzer (NanoString
Technologies) as per the manufacturer’s protocol with FOV set to 555. The expression
level of a gene was measured by counting the number of times the probe with a unique
barcode, which was targeted against that gene, was detected. The barcode counts were
then tabulated in a comma-separated value (.csv) format.

Q. NanoString nCounter data and statistical analysis
The raw digital counts of expressions were exported into nSolver Analysis
software (NanoString, version 4.0) for downstream analysis. The data was analyzed in
nSolver using the Nanostring Analysis and Advanced Analysis software packages. The
background of the data was thresholded using the geometric means after removing
negative control values that are three-times higher than the rest. The data was then
normalized using the geometric means of the positive controls, after removing “F” if the
value is too close to background, and the three housekeeping genes (Gapdh, Rpl4,
Tbp). Without removing low count values, the Bonferroni-corrected differentially
expressed gene (DEG) analysis of the normalized data was computed using Treatment
as covariates. For tubulin autoregulation panel, raw counts were exported, and statistical
analyses were carried as outlined below.
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R. Proximity Ligation Assay (PLA)
For desmin-EB1 and actinin-EB1 experiments, untreated isolated rat
cardiomyocytes were used. For EB-CLIP170 experiments, freshly isolated rat
cardiomyocytes were treated for 48 hours with Null, TTL, or E331Q adenoviruses at
37°C with 5% CO2. Once viral construct expressions were confirmed using the tagged
mCherry, the cardiomyocytes were glued to cleaned coverglass (EMS 72222-01) using
MyoTak (IonOptix). The cardiomyocytes on coverslips were fixed in 4%
paraformaldehyde for 10min at RT, followed by 2 washes in PBS, and then
permeabilized using 0.25% Triton in PBS for 10min at RT. The samples were blocked in
Sea Block overnight at 4°C and stored until further processing.
The samples were incubated with either desmin and EB1, or a-actinin and EB1,
or EB1 and CLIP-170 primary antibodies overnight at 4°C. The coverslips were then
washed in PBS with 0.1% Tween (PBST) for 10min at RT. Following immediately, PLA
was performed in humidified chambers using the manufacturer’s protocol starting with
“Duolink PLA Probe Incubation.” Briefly, the samples were incubated with Duolink PLA
secondary antibodies followed by ligation and amplification. Amplification was performed
using Duolink FarRed detection reagents (Sigma DUO92013). Post-amplified samples
were washed in PBS and incubated with 1:1000 405-Hoechst plus 1:200 488-WGA for
15min at RT for desmin-EB1 or a-actinin-EB1 experiments, or incubated with a-tubulin
antibody (DM1A) conjugated to AF 488 (Cell Signaling #8058S) in Sea Block overnight
at RT. The final processed samples were washed with PBST for 10min at RT then twice
with PBS, and the coverslips were mounted using ProLong Diamond Antifade Mountant
(Thermo Fisher P36961).
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S. Image Acquisition and Analysis
Imaging was performed using Zeiss AiryScan microscope. 1x 2µm slice per cell
or 6x 0.18µm slices were sampled for each cell in desmin-actinin-EB1 experiments and
EB1-CLIP170 experiments, respectively; 10 cells were sampled per group per
experiment (N=3, n=30). ImageJ was used to analyze the images. For desmin-actininEB1 experiment: an automated threshold image of the WGA channel was used to
identify the cell outline. The % Area coverage of the PLA puncta was then determined
using the cell outline. An average % Area coverage of all desmin-EB1 cells per
experiment was calculated to determine the relative fold-change of actinin-EB1 within
experiments. For EB1-CLIP170 experiment: an ROI was drawn to outline the
cardiomyocyte border and the microtubule-PLA overlap Raw Integrated Density (RID)
normalized to microtubule RID was calculated for each slice. The average microtubulePLA overlap RID for one cell is determined using information from the 6 slices. Finally,
the average value of all control cells in an experiment was used to calculate the relative
fold-change for each experiment.

T. Statistical Analysis
Graphing and statistical analyses were performed using OrginPro 2019 software
(OriginLabs). First, the normality of the data was determined using the Shapiro-Wilk test.
For comparison of data distributions whose normality cannot be rejected at 0.05 level,
the calculated probability of the means (p) between the control and the experimental
group was calculated using the two-tailed two-sample Welch-corrected student’s t-test.
For comparison of data distributions whose normality is rejected at 0.05 level, the pvalue between the control and the experimental group was calculated using the twotailed two-sample Kolmogorov-Smirnov test. For significance level, I used the
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Bonferroni-corrected significance cut-off of p < 0.025 denoted by * ; ** represents p <
0.01 and *** represents p < 0.001. P-values to two significant figures were reported for
0.05 < p < 0.025. For all bar graphs, the bar represents mean and the whisker
represents + 1 SEM. For all box plots, the bolded line represents mean, and the
whiskers represent ± 1 standard error of mean (SEM).

U. Raw Data Availability
The Nanostring data presented in the study have been deposited to the GEO
Omnibus repository with the accession number GSE194397. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the dataset identifier PXD031797.
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CHAPTER 3: RESULTS
A. Tubulin autoregulation is operant in the heart and induced in heart failure
Despite the importance of microtubule proliferation in cardiac pathology, any role
of tubulin autoregulation has not been examined. I utilized a previously established
strategy to test for autoregulation by measuring the relative abundances of pre-spliced
(i.e. intron-containing) and spliced (i.e. those without introns) tubulin mRNAs(Gasic et
al., 2019). Using this approach, one can detect transcriptional regulation of a target
through correlated changes in intronic and exonic mRNA levels (y = x in Fig. 2E, for
example), whereas post-transcriptional autoregulation would only affect exonic mRNA
(shift along the y-axis of Fig. 2E). To study autoregulation in an isoform-specific fashion,
I designed NanoString nCounter probes for direct and unique detection of either intronic
or exonic regions of individual tubulin isoforms. To determine if autoregulation is operant
in heart muscle cells, I treated isolated mouse cardiomyocytes for 6 hours with
colchicine, a microtubule depolymerizing agent predicted to trigger autoinhibition
(decrease in only exonic species) by increasing free tubulin, or taxol, a microtubule
polymerizing agent predicted to trigger autoactivation (increase in only exonic species)
by shifting free tubulin into the polymerized pool. Consistently, depolymerization
significantly reduced the amount of exonic but not intronic mRNA across most tubulin
isoforms, while polymerization increased the amount of exonic tubulin mRNA (Fig. 2DE). This data serves as the first demonstration that autoregulation is operant in the
cardiomyocyte and that it regulates the majority of tubulin isoforms.
Next, I tested whether tubulin autoregulation can partially explain the discrepancy
in mRNA and protein levels observed in heart failure. To this end, I designed a separate
Nanostring probe set against introns and exons of human tubulin isoforms and probed
RNA extracted from 35 cardiac samples from 12 non-failing donors and 23 patients with
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advanced heart failure. Figure 1F-G shows the relative intron and exon abundances for
all tubulin isoforms that could be readily detected at the intron, exon and protein level
(Chen et al., 2018)(Fig. 2A-B). In failing hearts, the majority of tubulin isoforms showed
reduced exonic relative to intronic levels, indicative of active autoinhibition across most
isoforms. An exception is TUBA1A, the only isoform that demonstrated significant
transcriptional induction; consistently TUBA1A is also being the only isoform to show
both increased and correlated mRNA and protein levels in this heart failure population
(Fig. 2A-B). Of additional note, TUBB4B is by far the most abundant b-tubulin isoform
expressed in the heart, and it exhibits robust autoinhibition in heart failure, yet maintains
increased protein abundance. Taken together this data indicates that in heart failure,
elevated tubulin protein triggers persistent autoinhibition of tubulin mRNA. The
maintained elevation in tubulin protein may be explained by significantly increased
tubulin stability/lifetime.
However, there remains no explanation as to how the heart achieved the
increased tubulin protein in the first place or whether autoregulation plays any role in the
establishment of the increased tubulin mass observed in pathological cardiac
remodeling. To better understand this, I employed mice models of cardiac hypertrophy
that allows us to explore the early roles of tubulin transcription, autoregulation, and
stability.

B. Acute adrenergic agonism induces anatomic and transcriptional cardiac
remodeling
To determine how the microtubule network remodels during the development of
cardiac hypertrophy, I characterized the myocardial cytoskeleton at two time points in
two mouse models of adrenergic agonist-induced hypertrophy(Scarborough et al., 2021)
29

(Fig. 3A). A 4-hour post-injection time point was chosen to capture a stage when hearts
were exposed to hypertrophic stimuli but have not yet hypertrophied, and a 4-day postinjection time point was chosen to capture a stage when hearts had demonstrably
hypertrophied. As expected, no change in heart-weight-to-tibia-length (HW/TL) was
observed 4 hours after injection of either phenylephrine (PE) or isoproterenol (Iso)
compared to vehicle control (Ctrl) (Fig. 3B, left). When mice were given a second
injection on day 2 and hearts were collected on day 4, I observed a consistent cardiac
hypertrophy with both PE and Iso (Fig. 3B, right).
Concurrently, I observed a similar increase in cardiomyocyte area in myocardial
tissue cross-sections (Fig. 4C). There was no mortality nor significant cardiac fibrosis in
control and experimental groups (Fig. 4D). To assess left-ventricular remodeling and
function, I performed echocardiography on the 4-day hypertrophy animals. I observed
consistent evidence of concentric hypertrophy upon both PE and Iso treatment, with
elevated left-ventricular (LV) mass and increased wall and septal thickness (Fig. 3C-D).
Neither group exhibited evidence of decompensation toward heart failure, with no
evidence of ventricular dilation or depressed contractility, indicating a compensated,
concentric hypertrophy in response to acute adrenergic agonism.
I further validated my models using NanoString nCounter to assess
transcriptional markers of cardiac remodeling in the hearts of PE and Iso treated mice.
Using direct RNA counting of 42 transcripts sorted into immediate early genes (IEGs),
hypertrophy-related genes, and fibrosis-related genes, I analyzed differentially
expressed genes (DEGs) in the septa and LV of my time-matched control and
experimental groups. I hypothesized that IEGs would be upregulated after 4-hours of
adrenergic stimulation, followed by upregulation of canonical markers of hypertrophic
remodeling after 4 days. Consistent with this hypothesis, I observed robust upregulation
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of the canonical IEGs – cMyc and cFos – in both PE and Iso treated mice at 4-hours
(Fig. 3E & Fig. 5), followed by induction of stress markers – Nppa and Nppb – at 4-days,
along with markers of fetal reprogramming including myosin isoform switching (reduced
Myh6:Myh7 ratio).
The full complement of DEGs in each experimental group at the 4-hour and 4day time points are depicted in Fig. 5. At both 4-hours and 4-days after adrenergic
agonism, I observed upregulation of hypertrophy-related gene Fhl1(Friedrich et al.,
2012), and fibrosis-related genes Ctgf (Hayata et al., 2008) & Vcan(Vistnes et al., 2014).
Additional potentially relevant DEGs included the upregulation of Col4a1(Steffensen and
Rasmussen, 2018) and Timp1(Barton et al., 2003), and the downregulation of
Agrn(Baehr et al., 2020; Bassat et al., 2017), among others (see discussion for further
contextualization).

C. The microtubule network is rapidly detyrosinated upon hypertrophic
stimulation
Having validated the 4-hour and 4-day models, I examined microtubule network
remodeling in these contexts. I first determined whether the total ab-tubulin content and
free vs. polymerized tubulin pools are altered in the pre-hypertrophic (4-hour) state. I
observed no significant differences in these metrics of total tubulin content or
fractionation at this early time point (Fig. 6A-C).
I next determined whether tubulin is rapidly post-translationally modified upon
hypertrophic stimulation. I immunoblotted for the five best-studied PTMs using validated
antibodies: acetylation, detyrosination, polyglutamylation, polyglycylation, and D2 tubulin.
Polyglutamylation, polyglycylation, and D2 are well characterized in cilia, flagella, and the
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brain(Aillaud et al., 2016; Paturle-Lafanechère et al., 1994), but they have not been
studied in the heart. Detyrosination and acetylation, which occur predominantly on
polymerized microtubules, are common markers of stable, long-lived microtubules, and
of microtubule damage and repair-stabilization processes(Portran et al., 2017; Xu et al.,
2017) respectively.
At the 4-hour time point, I did not observe any significant differences in either the
absolute (PTM/GAPDH) or the relative (PTM/a-tubulin) amounts of acetylation,
polyglutamylation, polyglycylation, or D2 tubulin (Fig. 6D, F-H). Surprisingly, I did
observe robust induction of the absolute and relative amounts of detyrosination in both
PE and Iso treated groups (Fig. 6E). These data suggest that within 4 hours of
hypertrophic stimulation, prior to other overt changes in tubulin mass, microtubules are
rapidly detyrosinated, which may serve as an early driver of microtubule stabilization.

D. Post-translationally modified microtubules proliferate during the
establishment of cardiac hypertrophy
I next characterized microtubule network remodeling at day 4, concurrent with
cardiac hypertrophy. I probed the 3 tubulin pools and immunoblotted for a-tubulin, btubulin, acetylation, detyrosination, polyglutamylation, polyglycylation, D2 as described
above.
At this stage I observed increased free, polymerized, and total ab-tubulin protein
in the hearts of PE and Iso-treated mice (Fig. 7A-C). In the PE group, the ratio of
free:polymerized a-tubulin decreased (Fig. 8A), consistent with enhanced microtubule
stability. In PE-treated mice, I observed increases in the absolute amounts of
acetylation, polyglutamylation, and polyglycylation, and in the absolute and relative
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amounts of detyrosination. Iso treated mice showed a similar trend for each PTM, but of
reduced magnitude and greater variability (Fig. 7C-H). Taken together, these data
indicate that during cardiac hypertrophy tubulin content increases, the polymerized
network densifies, and there is a proportionally increased abundance of posttranslationally modified microtubules with a modest enrichment of detyrosination.
I next sought to determine how specific tubulin isoforms contribute to the
increase in tubulin content observed at 4-days. To this end, I utilized mass spectrometric
(MS) analysis of the total tubulin pool. I observed that the predominant a- and b-tubulin
isoforms of murine LV were Tuba1a and Tubb4b, respectively (Fig. 9A). Each of these
predominant isoforms were modestly increased upon PE and Iso treatment. I also
determined the relative changes of all detectable tubulin isoforms and observed
significant increases in Tuba1a, Tuba1c, Tubb2a, Tubb2b, Tubb3, Tubb5, and Tubb6
(Fig. 9A-B). Of note, Tuba4a – the only tubulin isoform that is synthesized in its
detyrosinated form – was clearly not increased upon hypertrophic stimulation. This
indicates that the early increases in detyrosination are not due to increased synthesis of
Tuba4a, and instead likely due to altered activity of the enzymes of the tyrosination
cycle. Tubb6 exhibited the highest degree of upregulation with a ~4-fold increase upon
PE treatment; this is notable as Tubb6 induction has been causally implicated in
microtubule network reorganization in Duchenne Muscular Dystrophy(Randazzo et al.,
2019). Despite significant upregulation of multiple low abundance isoforms, the overall
composition of the total tubulin pool is largely conserved at this stage of hypertrophic
remodeling (Fig. 9A).
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E. Transcriptional analysis of ab-tubulin isoforms, tubulin modifying
enzymes, and MAPs during the induction and establishment of hypertrophy
I next examined the contribution of transcriptional changes to the protein and
network level microtubule remodeling at the 4-hour and 4-day timepoints. To this end, I
utilized NanoString analysis of total RNA using another set of 47 genes that includes
tubulin isoforms, tubulin modifying enzymes, and MAPs.
While tubulin protein content was unchanged 4-hours after adrenergic
stimulation, I noted significant upregulation of several tubulin transcripts with both PE
and Iso treatment at this stage, including Tuba1c, Tubb2a and Tubb6, with additional
and more robust upregulation of Tubb2b and Tubb3 by day 4 (Fig. 9C). Consistent with
proteomics assessments, Tuba4a and Tuba8 were either unchanged or even
downregulated upon PE and Iso treatment.
Regardless of the directionality of response, specific tubulin isoforms generally
responded similarly to either adrenergic stimulus (Fig. 9C). Further, in contrast to what
was observed in advanced heart failure, transcript levels were also well-correlated with
protein abundance across most isoforms at the 4-day time point (R2 = 0.38, slope = 0.20,
p = 1.4e-4) (Fig. 9D). Consistent with protein expression lagging transcriptional
regulation, the four isoforms (Tuba4a, Tuba8, Tubb2b, Tubb3) that displayed the
greatest deviation in the change in the mRNA relative to the change in the protein levels
(i.e. located furthest away from the y = x line when plotting log2FC of mRNA vs protein
levels) were transcripts that showed delayed regulation; these isoforms were unchanged
after 4-hours but differentially expressed by 4-days. Consistent upregulation at the
transcript and protein level was seen for Tuba1c, Tubb2a, Tubb2b, Tubb3, and Tubb6.
Combined with the early upregulation of tubulin transcripts, this data indicates that
increased tubulin mRNA at least partly underlies the isoform-specific increase in tubulin
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protein, and therefore tubulin mass, that is necessary for hypertrophic remodeling(Sato
et al., 1997; Scarborough et al., 2021; Tsutsui et al., 1999).
I noted several additional transcriptional changes of tubulin modifying enzymes
and MAPs that may bear relevance to cardiac remodeling and warrant further
investigation (Fig. 9E-F; Fig. 10). These include: (1) Vash2, which encodes a tubulin
detyrosinase, exhibited the greatest differential expression among the 47 assessed
transcripts at the 4-hr PE time point; this may contribute to the robust early induction of
detyrosination in this group (2) Early upregulation of Kif5b after 4-hours in PE(Tigchelaar
et al., 2016), which encodes the primary transport kinesin heavy chain 1 implicated in
mRNA transport during myocyte growth(Scarborough et al., 2021); (3) upregulation of
Mapre1 in both PE and Iso at 4-hours, which encodes a member of microtubule
associated protein RP/EB family of +TIP tracking protein that guides microtubule growth;
(4) Robust upregulation of Kif15 in both PE and Iso by 4-days, which encodes a kinesin
family member implicated in stabilizing parallel growing microtubules; (5) induction of
Map1a in both PE and Iso at 4-days, which encodes a stabilizing structural MAP.
I next sought to determine whether these mRNA changes were reflected at the
protein level for targets for which I could obtain robust signal via western blot from
validated antibodies. Generally, transcripts that were upregulated early at the 4-hour
time point such as Kif5b and Mapre1 also appeared to be upregulated at the protein
level by day 4, whereas transcripts that were unchanged or only upregulated later at 4days (such as Vash1 and Kif15), did not show protein level changes at day 4 (Fig. 8BC).
All tubulin-associated transcript volcano plots (Fig. 10) were asymmetric, tending
to show a greater degree of upregulated than downregulated genes, implying a
generalized induction of a tubulin-associated program at 4-days. This was particularly
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evident in the PE groups, and with progressive upregulation from the 4-hour to 4-day
time point. There were, however, notable down-regulated transcripts. While kinesin
isoforms, which encode plus-end directed anterograde motors, were generally
upregulated in treated groups, transcripts encoding subunits of the dynein/dynactin
minus-end directed motor (Dynll2, Dync1h1, Dctn2) were either downregulated or
unchanged (Fig. 9F). This preferential induction of anterograde motors would bias
trafficking toward the microtubule plus-end and away from the minus-end, which has
implications for directed cardiac growth and for autophagic flux, which requires minusend directed transport (McLendon et al., 2014). I also noted the early downregulation of
enzymes involved in the polyglutamylation cycle, such as cytosolic carboxypeptidase 5
(Ccp5) and TTL-like family members 1 and 5 (Ttll1/5), which were all reduced in PE and
Iso at the 4-hour time point (Fig. 10).
To determine the conservation of these tubulin-associated transcriptional
responses across varied hypertrophic stimuli, I compared my data with publicly available
RNA sequencing datasets from two separate studies that examined early time-points
following pressure-overload and angiotensin II induced hypertrophy. While data is not
available for all transcripts, transcripts that were consistently reported across studies
demonstrate well-conserved transcriptional signatures at both early (hours) and later
(days) timepoints (Fig. 11), including the consistent upregulation of most ab-tubulin
isoforms but with the notable downregulation of Tuba4a and Tuba8.

F. Transcriptional and autoregulatory mechanisms underlie isoform-specific
increases in ab-tubulin mRNA
The above transcriptional and proteomic profiling indicates that the upregulation
of tubulin mRNAs is an early driver of microtubule proliferation during the development
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of hypertrophy. This may arise from two non-exclusive mechanisms – (1) increased
transcription or (2) decreased autoregulation (i.e., autoactivation). To differentiate
between the two, I utilized the tubulin isoform and location -specific approach outlined
above to interrogate the mechanism of tubulin upregulation during cardiac hypertrophy.
Overall, I observed that by day 4 the exonic levels of almost all tubulin isoforms
increased more than intronic levels, suggesting a generalized autoactivation of tubulin
isoforms driven by microtubule stabilization (Fig. 12). The most prominent cases of
autoactivation are that of Tubb2b, whose increase in transcript level is solely through an
increase in exonic species at both 4-hours and 4-days, and Tuba1a, whose immediate
response at 4-hours was through an increase in exonic level with no change in intronic
level (Fig. 12A). Additionally, in a subset of the tubulin isoforms – Tuba1b, Tubb2a,
Tubb5, and Tubb6 – we observed robust increases in intronic levels that indicate direct
transcriptional activation by the hypertrophic stimuli (Fig. 12B, Fig. 13).
Interestingly, despite a generalized upregulation and autoactivation of tubulin
isoforms in the early stages of hypertrophy, Tuba4a and Tuba8 are downregulated and
autoinhibited, respectively. These data collectively show that ab-tubulin mRNA is
controlled in an isoform-specific and time-dependent fashion through both transcriptional
and autoregulatory mechanisms to rewrite the tubulin code during cardiac remodeling.
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CHAPTER 4: DISCUSSIONS & FUTURE DIRECTIONS
In this work, I combined transcriptomic and proteomic assessments of advanced
heart failure samples and temporally well-defined murine models of cardiac remodeling
to understand how a dense and modified microtubule network is achieved. Among other
observations expanded upon below, I arrive at four primary conclusions: 1) tubulin
autoregulation is operant in the heart and represses mRNA levels of tubulin isoforms in
heart failure, contributing to the observed discrepancy between tubulin RNA and protein
in heart failure; 2) the microtubule network is rapidly post-translationally detyrosinated
within 4 hours of a hypertrophic stimuli; 3) concomitantly, the abundance of tubulin
mRNA is rapidly altered in an isoform-specific fashion through both transcriptional and
autoregulatory mechanisms; 4) the time-dependent upregulation of discrete ab-tubulin
transcripts drives an increase in microtubule mass during cardiac hypertrophy.

A. Advantages of the acute adrenergic murine models of cardiac hypertrophy
To date, there is an abundance of animal models for cardiac hypertrophy such as
trans-aortic banding(Rockman et al., 1991), high-salt diet(Takeda et al., 2000; Yuan and
Leenen, 1991), and use of osmotic pumps to deliver adrenergic(Chang et al., 2018) and
angiotensin agonists (Balakumar et al., 2007). The advantages of these pre-existing
models are that they mimic the pathophysiology of cardiac hypertrophy and provide us
with an invaluable tool to study efficacy of interventions. However, the disadvantages are
that they need special technicians and can take variable amounts of time to establish
discernable hypertrophy; this unpredictability of how long it takes to observe the
hypertrophic phenotype makes it challenging to study the temporal aspects of the
pathological process. In the acute adrenergic stress-induced cardiac hypertrophy models
presented in this study, I was able to not only study the pathological changes associated
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with the microtubule network in the context of cardiac hypertrophy, but also elucidate the
time-dependent changes of the microtubules at all levels, i.e., network, protein, and
transcripts, as the heart transitions from a normal state to overt hypertrophy.

B. Temporal evaluation of previously identified cardiac hypertrophyassociated factors
In conjunction with the feasible of the models to be temporally controlled,
NanoString analyses of my hypothesized transcripts also yielded insightful observations
especially in associating transcriptional changes that had been previously described in
the cardiac hypertrophy literature but were temporally undetermined. To elaborate,
thrombospondin-4 (Thbs4)(Frolova et al., 2012; Palao et al., 2018), osteoblast specific
factor-2 (Osf2)(Lin et al., 2013), and lumican (Lum)(Engebretsen et al., 2013;
Mohammadzadeh et al., 2019) were all previously described to be upregulated in either
cardiac hypertrophy, heart failure, or both. Based on my data, I observed that the
upregulations of Thbs4 and Osf2 occurs in hypertrophy but not in pre-hypertrophy (Fig.
5). In addition, Lum is upregulated only when the heart has hypertrophied; in fact, Lum
was observed to be downregulated during pre-hypertrophic stage.

C. Evaluation of additional cytoskeletal elements
Beyond the key conclusions, several additional observations on additional
cytoskeletal remodeling are of note. The association of the microtubule network with
motor proteins such as kinesins alters its mechano-biochemical properties as well as its
density. As an example, Kif15 (kinesin-12) has been shown to cross-link nearby parallel
microtubules, causing them to bundle, and subsequently decreases the catastrophic
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events of dynamic microtubules(Drechsler and McAinsh, 2016). Interestingly, during
both PE and Iso -induced hypertrophy, Kif15 is upregulated, suggesting that Kif15 could
contribute to microtubule network densification.
Kif5b (Kinesin-1), the predominant anterograde motor in the heart, was
previously reported to be increased in PE induced-hypertrophy of neonatal rat ventricular
cardiomyocytes(Tigchelaar et al., 2016). I observed similar and rapid increase in Kif5b
transcript and protein levels in my hypertrophy models (Fig. 9F, Fig. 10). Kinesin-1 was
recently identified to be required for the distribution of mRNA and ribosomes that
enables cardiomyocyte hypertrophy (Scarborough et al., 2021), and past work indicates
that kinesin-1 prefers to transport cargo along detyrosinated microtubule tracks(Kaul et
al., 2014). Meanwhile, the dynein/dynactin retrograde motor protein complex
(transcriptionally downregulated, Fig. 9F), prefers tyrosinated microtubule tracks(Nirschl
et al., 2016). Taking together, these observations suggest that the heart both rapidly
induces its primary anterograde transport motor and remodels its preferred tracks in
response to a hypertrophic stimulus.
In addition to the suggestive time-dependent transcriptional changes, using my
NanoString data in conjunction with the microtubule characterizations, I observed
another interesting correlation. I observed an upregulation of Timp1(Barton et al., 2003)
and downregulation of Agrn(Bassat et al., 2017)(Fig. 5). Timp1 upregulation would lead
to an inhibition of extra-cellular matrix (ECM) degradation and a subsequent increase in
dystrophin-glycoprotein complex (DGC). Likewise, Agrn downregulation would also
increase DGC, through decreased association of agrin with a-dystroglycan and
subsequent ERK inactivation(Bassat et al., 2017). These two mechanisms could
potentially lead to stabilize microtubule network through increased DGC, and so the
increase in detyrosination at 4-hour could reflect this stabilization.
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D. Differential regulation of tubulin isoforms in muscle pathologies
Insights into tubulin isoforms in muscle biology have pointed towards the
potential detrimental effects of specific isoforms in muscle pathologies; for example,
TUBB6 is upregulated in dystrophic skeletal muscles, and it contributes to microtubule
disorganization and altered muscle regeneration in muscular dystrophy(Randazzo et al.,
2019). Elevated TUBA4A in human cardiomyopathy contributes to the increased
detyrosination that impedes myocyte function(Chen et al., 2018; Schuldt et al., 2020).
Strikingly, when I examine publicly available transcriptomic and proteomic data
from chronically hypertrophied or failing human hearts (Fig. 1A), I observe an inverse
relationship between the transcript and protein levels of almost all ab-tubulin isoforms. It
is worth noting that TUBA8 is the lone tubulin transcript that is consistently increased in
heart failure while the protein level is consistently decreased. Intriguingly, Tuba8 was
also the sole isoform to clearly escape autoactivation (and appear seemingly
autoinhibited) during early hypertrophic remodeling (Fig. 12A). I have no current
explanation for how or why Tuba8 shows unique regulation in both settings. In contrast
to this inverse relationship in heart failure, I observed that during the establishment of
hypertrophy, transcript and protein levels are highly correlated, suggesting an
uncoupling of transcript and protein levels that occurs later in the course of cardiac
remodeling. Chronic, robust microtubule stabilization and increased tubulin lifetime could
account for the stably elevated tubulin protein content despite persistent autoinhibition
that I observe in heart failure.
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E. Potential pathophysiological role of Tubb6 in cardiac hypertrophy
Moreover, given the fact that TUBB6 upregulation in dystrophic skeletal muscles
is causally linked to microtubule disorganization and altered muscle regeneration in
muscular dystrophy(Randazzo et al., 2019), it would fair to assume that the increase in
Tubb6 protein level during cardiac hypertrophy may also have a detrimental effect as
well. In line with this enquiry, studying the function of Tubb6 in cardiac biology using in
vitro and in vivo approaches is warranted. Furthermore, since I observed that the
increase transcription of Tubb6 gene underlies Tubb6 protein level increase, it would be
interesting to study the effects of Tubb6 knock-down during cardiac hypertrophy on
microtubules such as its dynamicity and viscoelasticity, and on cardiomyocyte such as
its contractility.

F. Tubulin isoform specificity of transcription and autoregulation
Although I have a good albeit incomplete understanding of how transcription
regulates total tubulin levels, I still lack knowledge of how it effects tubulin on an isoformspecific level. In line with this thinking, it would be interesting to unravel the transcription
factors involved in transcription of tubulin isoforms and to understand how changes to
the transcriptional programs can influence the isoform composition of microtubules and
hence its biomechanical properties. Preliminary analysis of the tubulin isoforms that are
deemed to be transcriptionally regulated at 4-hours post-hypertrophic stimuli showed
that Kruppel-like factor 4 (KLF4) binding motif is present in the promoter regions (data
not shown). It would be interesting to perform chromatin immunoprecipitation (ChIP)
experiment followed by NanoString nCounter analysis or RNA-sequencing to test the
hypothesis that KLF4 controls transcription of certain tubulin isoforms and that during
pathological conditions, this transcriptional regulation would change.
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Since only recently tubulin autoregulation was observed to regulate tubulin on an
isoform-specific level, it would be tremendously beneficial for the field of tubulin biology
to understand the molecular and genetic determinants of isoform-specificity. Although
the former would be harder to study, the latter could be accomplished by careful
mutagenesis experiments using model in vitro systems. Further interesting avenues
such as the crosstalk between tubulin isoforms, or the crosstalk between transcription
and autoregulation programs would serve well to have a complete understanding of
tubulin biology and to come up with unique treatment modalities for heart failure.

G. Subcellular localization of tubulin isoforms in cardiomyocyte
Since different tubulin isoforms are shown to have differing biochemical
properties and expression patterns, it would also be interesting to determine the subcellular localization of the tubulin isoforms before and after pathological stimulation using
RNA-FISH (fluorescent in situ hybridization). These experiments could potentially
uncover further regulations of tubulin isoforms not only at the level of expression through
transcription and autoregulation, but also at how the tubulin isoforms are utilized through
differences in its cellular location.

H. Role of intermediate filament, desmin, in cardiac hypertrophy
A recent in vitro study using optical traps to examine the biochemical interactions
between vimentin, an intermediate filament akin to muscle-specific desmin, and
microtubules, observed a direct interaction of vimentin and microtubules through
hydrophobic and electrostatic forces(Schaedel et al., 2021). I can hypothesize that a
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similar interaction between desmin and microtubule would be present in cardiomyocytes.
Indeed, recent work from my lab has shown that desmin and microtubules do interact,
and that their interaction decreases microtubule catastrophe and increases
growth(Salomon et al., 2021). From my current hypertrophy study in conjunction with
previous observations, an increase in detyrosination at 4-hour post-hypertrophic
stimulations suggests a possible mechanism in which the increased exposure of
charged amino-acid, glutamic acid, on tubulin C-terminal end through detyrosination
could reinforce the desmin-microtubule interaction to increase microtubule stability.
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CHAPTER 5: UNPUBLISHED DATA & CONCLUSIONS
A. Unpublished Data 1 – Desmin and tubulin tyrosination influences
microtubule stability
Recent unpublished data from the Prosser lab have shown that (1) loss of
desmin promotes microtubule catastrophes and prevents pausing of growing
microtubules on the sarcomere Z-disk, while (2) tubulin tyrosination promotes growth
and catastrophe frequencies (Salomon et al., 2021). However, two unanswered
questions remained: (1) is desmin directly interacting with microtubules and thus
stabilizing them or does it stabilize microtubules merely by being present at the Z-disk,
and (2) how does tubulin tyrosination promotes catastrophe?
To answer these two questions, I utilized an imaging approach known as
proximity-ligation assay (PLA) in which the proximity of two target proteins (baits) are
determined using target-specific antibodies; if two baits reside within 40nm, a PLA signal
will be observed whereas if the targets reside further than 40nm, no signal will be
observed. Using this approach, I first tested whether desmin and not the other
sarcomeric Z-disk protein, such as alpha-actinin, interacts with the microtubule. To
specifically test for desmin or alpha-actinin’s interaction with the growing microtubules, I
used desmin or a-actinin as the first bait and End-Binding Protein 1 (EB1) as the second
bait because EB1 is associated with the plus-end or the growing end of the microtubules
(Vitre et al., 2008). Indeed, EB1 interacts with both a-actinin and desmin at the Z-disk.
However, it was evident that EB1 preferentially interacts with desmin over a-actinin since
I observed a ~20-fold increase of PLA puncta in desmin-EB1 compared to a-actinin-EB1
(Fig. 15A).
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Next, I attempted to determine how tyrosinated microtubules exhibit increased
growth and catastrophe frequencies. It is unlikely that changes in the PTM alone would
lead to the observed phenotype (Khawaja et al., 1988; Webster et al., 1990). However,
the addition of hydrophobic tyrosine residue and the subsequent blocking of glutamic
residue will alter the hydrophobic and electrostatic interactions between the outer
surface of the polymerized microtubule and MAPs, enabling tyrosination to alter
microtubule dynamics through association with destabilizing MAPs or changes in MAP
composition on microtubules(Chen et al., 2021; Peris et al., 2009).
Recent in vitro microtubule reconstitution study suggests that synergistic binding
of EB1 and CLIP-170 on microtubules increases frequency of growth and catastrophe in
a tyrosination-dependent manner(Chen et al., 2021). Hence, I hypothesized that EB1
and CLIP-170 association will increase with tyrosination and this association is
independent of tubulin sequestration. To test this hypothesis, I performed PLA using
EB1 and CLIP-170 as baits in a three-group experiment in which I treated adult rat
cardiomyocytes with adenoviruses containing Null, TTL, or catalytically dead TTL (TTLE331Q), which sequesters tubulin like TTL but does not tyrosinate. To control for TTL or
E331Q induced microtubule network changes and to analyze only those EB1-CLIP-170
interactions on microtubules, I used total microtubule staining as a fiduciary marker.
Using image analysis, I determined the Raw Integrated Density (RID) of EB-CLIP170
PLA and microtubule overlap normalized to total microtubule (see methods for more
details). I observed that relative to the Null, TTL cardiomyocytes exhibited increased
EB1 and CLIP-170 association on microtubules; this increase is independent of tubulin
sequestration since EB1-CLIP-170 association remains unchanged in E331Q
cardiomyocytes compared to control (Fig. 15B). Collectively, the data suggest that the
increased growth and catastrophe frequencies of tyrosinated microtubules is partly
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mediated through tyrosination-dependent association of EB1 and CLIP-170 in
cardiomyocytes.

B. Unpublished Data 2 – Tubulin tyrosination improves cardiac function
during hypertrophy
Given my observation that detyrosination of cardiac microtubules increased
within 4 hours following a pathological stimulus, I wondered whether detyrosination of
microtubules could be causal in the development of early adaptive hypertrophy. I
therefore hypothesized that microtubule detyrosination is required for the induction of
cardiac hypertrophy.
To test this hypothesis, I initiated a pilot experiment in which I attempt to rescue
the phenylephrine-induced hypertrophy using adenovirus (Adv) mediated
overexpression of tubulin tyrosine ligase (TTL) prior to administration of phenylephrine.
In collaboration with a post-doctoral fellow in the Prosser Lab, I retro-orbitally injected
five 6-weeks old C57/Bl6 mice with saline or four 6-weeks old C57/Bl6 mice with AdvTTL and let the virus to be transduced for 2 weeks. After 2 weeks when the mice
reached 8 weeks of age, I challenged all nine animals with phenylephrine on day 0 and
day 2 and collected the heart tissues on day 4. I then measured the HW/TL and
performed western blot to discern the amount of TTL overexpression.
As shown in Fig. 16, TTL was overexpressed robustly in the cardiac tissues of
Adv-TTL 8-weeks old mice. Although I observed a slight decrease in the HW/TL in AdvTTL group, I did not observe any significant differences in the heart-weight-to-body
weight or HW/TL ratios (Fig. 16). I wondered whether this insignificant reduction of
HW/TL in the Adv-TTL group compared to saline group could be made significant by
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increasing the extent of phenylephrine-induced hypertrophy so that there is more room
to observe the rescue effect by TTL overexpression.
To this end, I attempted to induce a greater degree of cardiac hypertrophy than
what was previously observed by increasing the number of phenylephrine or
isoproterenol injections from two to nine. I again utilized C57/Bl6 wild-type mice (5 mice
per experiment) and injected with either 10mg/kg phenylephrine or 5mg/kg isoproterenol
or ascorbic acid control every other day starting at day 1 for a total of 9 injections. To
test the rescue effect of TTL overexpression, I also included a group of five additional
mice, in which I injected Adv-TTL retro-orbitally at 6 weeks of age and injected them with
phenylephrine after two weeks at 8 weeks of age, for a total of 9 injections (Fig. 17A).
In addition to harvesting heart tissues at the end of the experiment on day 19 to
determine the HW/TL (Fig. 17B) and microtubule post-translational modifications (Fig.
18) using western blot analysis, I ascertained the cardiac functions of the control,
phenylephrine, and phenylephrine + TTL mice using extensive echocardiography
analysis on days 5, 12, and 19. During the experiment, there was only two mortalities in
the long-term isoproterenol injected group (data not shown). The full suite of
echocardiography data for day 19 is presented in Figure 17C. Interestingly, as shown in
figure 17A, I no longer observed the phenylephrine and isoproterenol induced
hypertrophy phenotypes on day 19. This null observation could be attributable to badrenergic signal desensitization of the experimental animals due to chronic
phenylephrine exposure(Dewenter et al., 2022; Najafi et al., 2016).
Despite the null observation in the HW/TL metric in the control and TTL
overexpressed groups, I did observe significant changes in multiple echocardiographic
parameters of the experimental animals on day 19. Experimental animals in the
phenylephrine alone group did show increases in Left-Ventricular Mass Index (LVMI)
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and Isovolumic Relaxation Time (IVRT), suggesting that the heart did undergo
phenylephrine-induced hypertrophy and that this hypertrophy is accompanied by slower
rates of isovolumic relaxation and diastolic strain (Fig. 17C). Interestingly, TTL
overexpression seems to block phenylephrine-induced hypertrophy as well as the
aberrant isovolumic relaxation and diastolic strain phenotypes.
Finally, western blot analyses of the tubulin PTMs (Fig. 18) showed a decrease
of detyrosination in TTL overexpressed group along with a decrease in D2 tubulin
formation and an increase in polyglutamylation. The decreased in detyrosinated and D2
tubulin in the TTL overexpressed group is expected given that TTL catalyzes tyrosination
and detyrosinated tubulin is the substrate for D2 formation. All in all, my preliminary data
on the effects of TTL overexpression before phenylephrine-induced hypertrophy shows
promising results in which TTL overexpression blocks hypertrophic phenotype while
improving aberrant cardiac functions that are associated with cardiac hypertrophy. This
study could be of interest in future studies to elucidate and ascertain the role of
microtubule detyrosination in mediating cardiac hypertrophy and its associated functional
declines.

C. Conclusions
The data I have presented thus far in my thesis support the conclusions that (1)
in addition to tubulin post-translational modifications, tubulin isoforms remodel rapidly
during cardiac pathology through concerted mechanisms of transcription and posttranscriptional autoregulation, and (2) through understanding the regulations of the
tubulin code, we can modulate the properties of the microtubule network and one day
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discover novel microtubule-centric therapies that can stop the progression of
hypertrophy into heart failure.
Some limitations of this study include the use of animal models for hypertrophy to
study tubulin isoforms, and the lack of tubulin isoform data from animal models of heart
failure. Given the differences in the expressed tubulin isoforms between human and
mice, the findings on which tubulin isoforms are controlled transcriptionally or
autoregulationally presented above should be interpreted in appropriate context of
murine models. Another limitation is the use of total cardiac tissue that comprises of
different cell types; however, it is important to note that cardiomyocytes make up ~56%
of all cells or 70-80% by mass, which means that the changes observed in total cardiac
tissue can be attributed mostly due to changes in the cardiomyocytes.
Combining this work with past literature, I propose the following sequential model
for the formation of a proliferated and stabilized microtubule network in the remodeled
heart (Fig. 14). Within hours of a hypertrophic stimuli and prior to detectable growth, the
microtubule network is detyrosinated (Fig. 7E). my data indicate that this increase in
detyrosination is likely due to transcriptional (Fig. 9E) or post-translational(Yu et al.,
2021) upregulation of the recently identified detyrosinating enzyme complex, as my data
argues against alternative mechanisms such as increased Tuba4a expression (Fig. 9C),
increased polymerized or long-lasting microtubule substrate (Fig. 6C-D), or decreased
TTL expression (Fig. 8B-C). Detyrosination serves as a network stabilizer to protect
microtubules from breaking down by regulating EB1-CLIP170 association on
microtubules (Fig. 15B) or through its interaction with the desmin intermediate filament
(Fig. 15A); reduction of detyrosination by overexpressing TTL can prevent adrenergicinduced cardiac hypertrophy (Fig. 17). Microtubule stabilization, in turn, shuttles free
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tubulin into the polymerized microtubule pool, triggering autoactivation that increases
tubulin mRNA stability and translation.
How autoregulation may achieve isoform-specificity is not understood, although
indicated by my data (see Tubb2b vs. Tuba8, Fig. 12). In concert with posttranscriptional upregulation of tubulin mRNA, increased transcription of several isoforms
concomitantly increases tubulin mRNA. Independent of the mode of upregulation, tubulin
mRNAs appear to be efficiently translated, as mRNA levels are well correlated with
peptide abundance across tubulin isoforms (Fig. 9D). As the stimuli persists and the
heart enlarges, the newly translated tubulin is integrated into the microtubule network,
resulting in increased microtubule mass and additional substrate for post-translational
modifications (Fig. 7). Finally, I showed that by preventing microtubule detyrosination,
we can prevent the onset of cardiac hypertrophy following pathological stimulation.
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APPENDICES
A. Appendix A: Figures

Figure 1. Summary of the tubulin code.

(A) Free & polymerized tubulins are in dynamic equilibrium.

(B) The tubulin code is the permutation of the tubulin post-translational modifications &
isoforms.
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Figure 2. Tubulin autoregulation is operant in the heart and activated in heart failure.
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(A) Heatmaps of previously published mRNA (left) & protein (right) data of human αβtubulin isoforms during dilated (DCM), ischemic (ICM), & hypertrophic (HCM)
cardiomyopathies.

(B) Scatter-plot of log2fold-change of mRNA on x-axis and log2fold-change of protein on
y-axis in heart failure; each data point represents an average log2fold-change value from
DCM and ICM groups from (A), and y = x represents a proportionate change between
mRNA and peptide.

(C) Schematic of tubulin autoregulation: The introns of tubulin pre-mRNA are spliced out
and the mRNA is fully translated in the absence of excess free tubulin; in the presence
of excess free tubulin, the mRNA, but not the pre-mRNA, is degraded.

(D) Relative log2fold-change of mRNA counts of intronic (left) and exonic (right) αβtubulin isoforms in isolated adult mouse cardiomyocytes after treatment with either
depolymerizing (Colch) or polymerizing (Tax) agents (n=3); whiskers represent ± 1SEM,
bolded line represents mean, * represents p-value from Welch-corrected two-tailed twosample t-test on non-log data < 0.025 (Bonferroni-corrected for two comparisons), **
represents p < 0.01, and *** represents p < 0.001.

(E) Scatter-plot of relative log2fold-change of intron on x-axis and exon on y-axis after
Colch or Tax treatment in adult mouse cardiomyocytes; whiskers represent ± 1SEM.

(F) Scatter-plot of relative log2fold-change of intron on x-axis and exon on y-axis in nearnormal and failing patient heart samples; whiskers represent ± 1SEM.
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(G) Relative fold-change of mRNA counts of intronic and exonic αβ-tubulin isoforms in
near-normal and failing patient heart samples; whiskers represent ± 1SEM, bolded line
represents mean, and p-values are from Welch-corrected two-tailed two-sample t-test.
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Figure 3. Acute α- or β- adrenergic stimulation induces cardiac hypertrophy.

(A) Graphical scheme of the experimental plan.
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(B) Heart-weight / Tibia length (HW/TL) data of mice 4-hours (n=6) or 4-days (n = Ctrl:7,
PE:7, Iso:6) following 10mg/kg/injection of phenylephrine (PE) or 5mg/kg/injection of
isoproterenol (Iso).
(C) Representative echocardiographic M-mode images of 4-day mice hearts.

(D) Quantification of relevant echocardiographic parameters: FS = Fractional Shortening,
LVIDd = Left-Ventricular Internal Diameter at end diastole, RWT = Relative Wall
Thickness, LVMI = Left-Ventricular Mass Index, LVPWd = Left-Ventricular Posterior Wall
thickness at end diastole, IVSd = InterVentricular Septal thickness at end diastole (n=8).

(E) Relative log2fold-change of nCounter mRNA counts of Immediate Early Genes
(IEGs), hypertrophic stress markers, and genes of fetal reprogramming (n = 4h: 6, 4d:
Ctrl:7, PE:7, Iso:6).

For all box plots, whiskers represent ± 1SEM and bolded-lines represent mean. For (B)
and (D), * represents p-value from Welch-corrected two-tailed two-sample student’s ttest < 0.025, ** represents p < 0.01, and *** represents p < 0.001.

For (E), * represents Bonferroni adjusted (for 45 genes) p-value < 0.025 (Bonferronicorrected for two comparisons), ** represents adj_p < 0.01, and *** represents adj_p <
0.001 (see Methods for more statistical details).
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Figure 4. Tubulin isoform C-terminal amino acid sequences and 4-day cardiac histology.

(A) C-terminal amino-acid sequences of mouse a- and b- tubulin isoforms.

(B) Representative histological images of 4-day mice hearts.
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(C) Cell-size quantifications from 4-day mice histology images (30 cells per image, 3
images per mouse, 3 mice per treatment); bolded line represents mean, * represents pvalue from Welch-corrected two-tailed two-sample student’s t-test < 0.025, ** represents
p < 0.01, and *** represents p < 0.001.

(D) Fibrosis quantifications from 4-day mice Masson Trichome stained histology images;
whisker represents ± 1SEM and bolded-line represents mean.
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Figure 5. Full data suite from hypertrophy and fibrosis panel

(A) Principal component analysis (PCA) of nCounter mRNA counts from 4-hour and 4day mice heart tissues using the hypertrophy & fibrosis panel.

(B) Relative log2fold-change of nCounter mRNA counts of hypertrophy-related genes,
temporally regulated hypertrophy-related genes, and extracellular-matrix-related genes.
(n = 4h: 6, 4d: Ctrl:7, PE:7, Iso:6).

Volcano plots of all mRNA counts from the hypertrophy & fibrosis panel for (C) 4-hour
PE, (D) 4-hour Iso, (E) 4-day PE, & (F) 4-day Iso. (n = 4h:6, 4d: Ctrl:7, PE:7, Iso:6)
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Figure 6. The microtubule network is rapidly detyrosinated upon hypertrophic
stimulation.

Representative immunblots and relative fold-change of α-tubulin (left) and β-tubulin
(right) in (A) total proteins, (B) free or (C) polymerized -tubulin fractions (n=6).

Representative immunoblots with technical duplicate lanes and relative fold-change
using GAPDH (left) or α-tubulin (right) as loading controls for (D) acetylated α-tubulin,
(E) detyrosinated α-tubulin, (F) Δ2 α-tubulin, (G) polyglutamylated α-tubulin, & (H)
polyglycylated pan-tubulin (n=6).

For all bar plots, whiskers represent + 1SEM and bar represents mean. For all graphs, *
represents p-value from Welch-corrected two-tailed two-sample t-test < 0.025
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(Bonferroni-corrected for two comparisons), ** represents p < 0.01, and *** represents p
< 0.001.

71

Figure 7. Total tubulin content increases & the microtubule network densifies during
hypertrophy.

Representative immunoblots and relative fold-change of α-tubulin (left) and β-tubulin
(right) in the (A) total proteins, (B) free, or (C) polymerized -tubulin fractions (n = Ctrl:7,
PE:7, Iso:6).

Representative immuno- blots with technical duplicate lanes and relative fold-change
using GAPDH (left) or α-tubulin (right) as loading controls for (D) acetylated α-tubulin,
(E) detyrosinated α-tubulin, (F) Δ2 α-tubulin, (G) polyglutamylated α-tubulin, & (H)
polyglycylated pan-tubulin (n = Ctrl:7, PE:7, Iso:6).
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For all bar plots, whiskers represent + 1SEM and bar represents mean; * represents pvalue from Welch-corrected two-tailed two-sample t-test < 0.025 (Bonferroni-corrected
for two comparisons), ** represents p < 0.01, and *** represents p < 0.001.
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Figure 8. Additional protein level characterization of 4-hour and 4-day samples.

(A) Free/Poly quantifications for α and β -tubulins at 4-hour (left) and 4-day (right).

(B) Western blot analyses of TTL, Kif5b, and Kif15 at 4-hour. (n: Ctrl, PE, Iso = 6)

(C) Western blot analyses of TTL, Kif5b, Kif15, Vash1, and Mapre1 at 4-day. (n: Ctrl=7,
PE=7, Iso=6). For Mapre1, we provided quantifications of two prominent bands at
different molecular weights that were changed in the experimental groups: 30kDa band,
which is the predicted molecular weight according to the amino acid sequence, and
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50kDa band, which is also observed using the Anti-EB1 antibody produced in rabbit
(Sigma: E3406) in certain cell types. For all graphs, * represents p-value from Welchcorrected two-tailed two-sample t-test < 0.025, ** represents p < 0.01, and *** represents
p < 0.001.
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Figure 9. Differential expression of tubulin isoforms, modifying enzymes and MAPs
during the onset and establishment of hypertrophy.
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(A) MS counts of unique peptides of detectable αβ-tubulin isoforms at 4-day timepoint.
For all following box plots, whiskers represent ± 1SEM and bolded line represents mean.

(B) Relative log2fold-change of αβ-tubulin isoforms peptide counts at 4-days (n = Ctrl:4,
PE:5, Iso:4); * represents p-value from Welch-corrected two-tailed two-sample t-test on
non-log data < 0.025 (Bonferroni-corrected for two comparisons), ** represents p < 0.01,
and *** represents p < 0.001.

(C) relative log2fold-change of nCounter mRNA counts of detectable tubulin isoforms at
4-hour (left) (n=6) and 4-day timepoints (right) (n = Ctrl:7, PE:7, Iso:6); * represents
Bonferroni adjusted (for 50 genes) p-value < 0.025, ** represents adj_p < 0.01, and ***
represents adj_p < 0.001 (see Methods & Materials for more statistical details).

(D) Scatter-plot of log2fold-change of mRNA on x-axis and log2fold-change of protein on
y-axis at 4-day timepoint; whiskers represent ± 1SEM and y = x represents a
proportionate change between mRNA and peptide.

Relative log2fold-change of nCounter mRNA counts of (E) detyrosinase complex and
tyrosinase, & (F) MAPs, anterograde, & retrograde motors at 4-hour (n=6) and 4-day
timepoints (n = Ctrl:7, PE:7, Iso:6); * represents Bonferroni adjusted (for 50 genes) pvalue < 0.025, ** represents adj_p < 0.01, and *** represents adj_p < 0.001 (see
Methods for more statistical details).
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Figure 10. Full data suite from tubulin isoforms, tubulin modifying enzymes, and
molecular motors panel.

78

(A) Principal component analysis (PCA) of nCounter mRNA counts from 4-hour and 4day mice heart tissues using the tubulin panel.

Volcano plots of all mRNA counts from the tubulin panel for (B) 4-hour PE, (C) 4-hour
Iso, (D) 4-day PE, & (E) 4-day Iso. (n = 4h:6, 4d: Ctrl:7, PE:7, Iso:6)
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Figure 11. Previously published & current studies’ mRNA data of mouse ab-tubulin
isoforms following different pathological stimulations (Bottermann et al., 2018,
Doroudgar et al., 2019).
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Figure 12. Tubulin isoforms are differentially regulated at the mRNA level through
isoform-specific transcription and/or autoregulation during cardiac hypertrophy.

Relative log2fold-change of mRNA counts of αβ-tubulin isoforms that are predominantly
regulated through

(A) autoregulation, or (B) transcription (n = 4h: 6, 4d: Ctrl:7, PE:7, Iso:6); * represents pvalue from Welch-corrected two-tailed two-sample t-test on non-log data < 0.025
(Bonferroni-corrected for two comparisons), ** represents p < 0.01, and *** represents p
< 0.001.
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Scatter-plots of relative log2fold-change of intron on x-axis and exon on y-axis at (C) 4hour and (D) 4-day timepoints; whiskers represent ± 1SEM.
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Figure 13. Unspliced and spliced mRNA counts of Tuba1b and Tubb5 (n = 4h:6, 4d:
Ctrl:7, PE:7, Iso:6); * represents p-value from Welch-corrected two-tailed two-sample ttest on non-log data < 0.025 (Bonferroni-corrected for two comparisons), ** represents p
< 0.01, and *** represents p < 0.001.

83

Figure 14. Proposed schematic model.
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Figure 15. Unpublished results from how desmin and tubulin tyrosination influences
microtubule stability.

(A) Representative images of a-actinin-EB1 (left) or desmin-EB1 (right) interactions in
untreated rat cardiomyocytes, along with the quantifications (N = 3, n = 30). Box
represents 25th and 75th percentiles, line represents mean, error bar represents ± 1 SD,
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and *** represents p-value from Welch-corrected two-tailed two-sample t-test on non-log
data < 0.01.

(B) Representative images of EB1-CLIP170 interactions on microtubules in Null, TTL,
E331Q treated rat cardiomyocytes, along with the quantifications (N = 3, n = 30). Bar
represents mean, error bar represents ± 1 SE, and *** represents p-value from one-way
ANOVA test < 0.01.
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Figure 16. Unpublished results from pilot experiment to test the rescue effects of TTL
overexpression in phenylephrine-induced hypertrophy.

(A) Schematic of the experiment

(B) Western-blot image, with duplicate technical lanes, and analysis of a-tubulin and
TTL. Box represents 25th and 75th percentiles, line represents mean, and error bars
represent mean ± 1 SE; p-values are from Welch-corrected two-tailed two-sample t-test.
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(C) Body weight, heart weight, and tibia length measurements along with heart-weightto-body weight and HW/TL ratios. Bar represents mean and error bars represent mean ±
1.5 SE
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Figure 17. Unpublished results from second pilot experiment to determine the extent of
long-term phenylephrine or isoproterenol induced hypertrophy and the rescue effects of
TTL overexpression in this phenylephrine-induced hypertrophy system.

(A) Schematic of the experiment

(B) Heart weight, left-ventricular weight, and tibia length measurements along with
HW/TL and left-ventricle-weight-to-tibia-length ratios. Line represents mean and error
bars represent mean ± 1.5 SE.

(C) Day 19 echocardiographic analysis of ascorbic acid, phenylephrine, and
phenylephrine + TTL treated mice; p-values are from one-way ANOVA using treatment
as the factor.
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Figure 18. Unpublished western blot analysis of a-tubulin post-translational
modifications during long-term phenylephrine and isoproterenol induced hypertrophies.
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(A) Western blot images of a-tubulin and its post-translational modifications

Relative fold-change using GAPDH as loading controls for (B) α-tubulin, & (C) TTL (n =
Ctrl, PE, PE+TTL = 5, Iso = 3). Since multiple western blots were ran to determine the
levels of different post-translational modification with respect to α-tubulin, multiple total
α-tubulin data points were obtained n = Ctrl, PE, PE+TTL = 5, Iso = 3 were obtained.
The data in (B) represents all total α-tubulin data points.

Relative fold-change using GAPDH (left) or α-tubulin (right) as loading controls for (D)
detyrosinated α-tubulin, (E) acetylated α-tubulin, (F) polyglutamylated α-tubulin, & (G) Δ2
α-tubulin (n = Ctrl, PE, PE+TTL = 5, Iso = 3).

For all bar plots, whiskers represent + 1SEM and bar represents mean; significant pvalue from Welch-corrected two-tailed two-sample t-test are indicated on the bars.
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B. Appendix B: Tables

Target

Vendor

Total a-tubulin
Total a-tubulin
Total b-tubulin
Acetylated atubulin
Detyrosinated atubulin
Polyglutamylated
a-tubulin
D2 a-tubulin
Polyglycylated
tubulin
Kif15
Vash1

Abcam
Abcam
Abcam

Host
Species
Mouse
Rabbit
Rabbit

Abcam

Mapre1 (EB1)
CLIP-170
Desmin
a-actinin
GAPDH
H3
Anti-mouse
Anti-rabbit

Clonal

Product No.

Mono
Poly
Poly

ab7291
ab4074
ab6046

Concentration
used (1: )
3000
2000
1500

Mouse

Mono

ab24610

1000

Abcam

Rabbit

Poly

ab48389

1000

Adipogen

Mouse

Mono

50-436-394

500

Moutin Lab
EMD
Millipore
Proteintech
Abcam
SigmaAldrich
Santa Cruz
Agilent
Abcam
GenScript
Abcam
LI-COR
LI-COR

Rabbit

Poly

Mouse

Mono

MABS276

700

Rabbit
Rabbit

Poly
Mono

55407-1-AP
ab199732

Rabbit

Poly

E3406

Mouse
Mouse
Mouse
Mouse
Mouse
Donkey
Donkey

Mono
Mono
Mono
Mono
Mono
Poly
Poly

sc-28325
M076029-2
ab9465
A01622-40
ab24834
925-32212
925-68073

500
1000
WB: 500,
PLA: 400
PLA: 100
PLA: 500
PLA: 1000
2000
3000
10000
10000

5000

Table 1: Primary and secondary antibodies used in this thesis.
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Customer
Identifier

Accession

Position

Target Sequence

Tm CP

Tm RP

CCP3

NM_178630.3

1047-1146

AGAGCCTGTTTACCCAAACTCCAAGGAAGATACTGTGGTTTATTTAGCTGAA
GATGCTTACAAAGAGCCCTGTTTTGTGTATTCCCGAGTTGGGGGTAAC

79

80

CCP5

NM_001048192.2

919-1018

TCCGTTTCACAGGCAAAAGGATATTCTTCTTAAGCAGTAGGGTACACCCTGG
AGAGACTCCATCTAGCTTTGTGTTCAATGGCTTTCTGGACTTCATCCT

80

79

CCP1

NM_001048008.2

399-498

CAGACTGTACTTAATATCCTAAGCATTCTCATTGAGCTGGTGTCATCGGGTG
GGGGTCGAAGAGCGAGTTTCTTAGTTGCCAAAGGTGGTTCACAAATAC

78

82

ATAT1

NM_001142744.1

199-298

AAGGCGCAGCACCTCCCTGCACCCATCACCAGCGCTTTGAGGATGCAAAGC
AACCGGCACGTTATTTACATACTGAAGGACACCTCAGCCCGACCGGCAG

83

82

Clip1

NM_019765.4

279-378

GCCCTCCATCCTCCGAGACCCAAGAGGAGTTTGTGGATGACTTTCGAGTTGG
AGAACGTGTTTGGGTGAACGGGAATAAGCCCGGATTTATCCAGTTTCT

82

80

Clip2

NM_009990.3

1017-1116

CCTGCGGGAGAGTGTTCTTAACAGCTCAGTGAAGACGGGCAATGAGTCTGG
TTCCAACCTCTCCGACAGTGGTTCTGTGAAGCGCGGTGACAAGGACCTC

82

82

Dctn2

NM_001190453.1

1631-1730

GCCCAGCCACATGCAGTTCCCGTCCAGTAAGTGCTTTGCCTGCTGTGGGAG
AGGGACTGGATCCCGTCCTCTAACGTCTGTCTCTGGCCGAGTCTAACAC

82

82

Dync1h1

NM_030238.2

5945-6044

AGTCCGTCAAAGCCCTCGGCCATCAGCTGGGGCGGTTCGTCTTAGTTTTCAA
CTGTGACGAAACCTTTGATTTCCAGGCGATGGGACGTATCTTTGTGGG

82

80

Dynll2

NM_026556.4

2373-2472

TTTGTTCATCTCTCATTTCTGGTGCAGTGACTGAGACCCTGCCACATCTATGC
TCTGCATCCACGCCTCTTTTGGACATTAAAGGTCGATTGATGCACTT

79

79

GAPDH

NM_001001303.1

891-990

AGGTTGTCTCCTGCGACTTCAACAGCAACTCCCACTCTTCCACCTTCGATGCC
GGGGCTGGCATTGCTCTCAATGACAACTTTGTCAAGCTCATTTCCTG

81

79

Hdac6

NM_010413.3

565-664

GATCTGAACCCTGAGACAAGAGTGCCAGTTGGTACTGGATTGGTGTTTGATG
AACAACTAAATGACTTCCATTGCCTTTGGGATGACAGCTTCCCTGAAA

81

81

Kif15

NM_010620.1

515-614

TGGAGCTGGGAAGAGTTTCCTTTGTAAGTGCTCCTTTATTGAGGTCTACAAT
GAGCAGATATATGACCTCCTGGACTCGGCGTCAGTCGGACTGTATTTG

78

82

Kif2c

NM_134471.3

916-1015

CAAGTGTCTCCTCCTGGTGCATGAACCCAAGTTAAAAGTGGACTTAACGAAG
TACCTGGAGAACCAAGCTTTCTGCTTTGACTTTGCATTTGATGAGACA

82

79

Kif5b

NM_008448.3

1778-1877

TGGATCAGGAAGAGCTTCTGGCATCAACCAGAAGGGATCAAGATAATATGC
AAGCTGAACTGAATCGCCTCCAAGCAGAAAATGATGCTTCTAAAGAAGA

86

84

Map1a

NM_001173506.1

197-296

TCAGCTCACAAACTCCTCATCTTGAGTGGACAAACTTTAGAACCCGAGGGAG
ACCTTATCCTACAGAGTGGTACTTACTCATATCAAAACTTCGCCCAGG

82

81

Map4

NM_008633.4

3225-3324

GTCCAAAGCTAATATCAAGCACAAGCCTGGTGGAGGAGATGTCAAGATTGA
AAGTCAGAAGTTGAACTTCAAGGAGAAGGCCCAAGCCAAAGTGGGATCC

85

86

Mapre1

NM_007896.3

161-260

TCAGTCACCAGTGATAACCTAAGTCGACATGACATGCTGGCTTGGATCAATG
AATCTCTGCAGTTGAATCTGACAAAGATAGAACAGTTGTGTTCAGGGG

82

81

Mapre2

NM_001162941.1

3134-3233

AAAAATGTTCCCTGGCTAGTGTACTCCATTCTCTTTCCTAGTGGCTCGGGCCA
GACTTCATCCATTTAGAGAGAAGCAGTACTTCCTGTTTGTGTGCCCA

80

78

Mapre3

NM_133350.1

169-268

TCCACTTCTGTGACCAGTGAGAATCTGAGTCGCCATGATATGCTTGCATGGG
TCAATGACTCTCTGCACCTCAATTATACCAAGATTGAACAGCTCTGTT

83

80

Mapt

NM_001038609.2

1203-1302

CAGTCGAAGATTGGCTCCTTGGATAATATCACCCACGTCCCTGGAGGAGGG
AATAAGAAGATTGAAACCCACAAGCTGACCTTCAGGGAGAATGCCAAAG

86

87

Rpl4

NM_024212.4

1323-1422

ATTCCAGAGAGCAAGTAGAGACCGCATATTTCAATAAATCAAACATGTGGTGACAAACCCT
TGTGTGACTCTTAAATTGTGGATGTTTCCAAGCCCCTTG

78

78

Svbp

NM_001038998.2

557-656

CTGAGCTGGCCCAATGGAGCCTTACAGAACTAATCAGGACTTGTGGAGACC
TCTGCACTGAACTTCCTATAAGTAACTTCCACCACACTGGTTTCTACTC

83

80

Tbp

NM_013684.3

71-170

GTGGCGGGTATCTGCTGGCGGTTTGGCTAGGTTTCTGCGGTCGCGTCATTTTCTCCGCAG
TGCCCAGCATCACTATTTCATGGTGTGTGAAGATAACCCA

83

79

TTL

NM_027192.2

1539-1638

GAGAGCCCAGCACTTCTCTGAAGGGCTGGGACCAGGGATTTGTTATGGCGT
GATCTGATCCTTTGAGCGGTTTCTGGCCTTGGATGGTACTGGGAACAGA

82

82

TTLL1

NM_178869.4

895-994

GTGTCGCAGTCCACAAAAGAAGCGTACGTGATCTCAGTCTATATCAATAATC
CGTTGCTCATCGGTGGAAGGAAGTTTGACCTTCGTCTGTATGTCCTGG

78

80

TTLL11

NM_028921.2

2499-2598

GCCTGCTGGTCAGAGCTTAGCATCATCGCATGTCTTTCCTTCTGCCCATTGCC
TGAAACGAAGTTGAAATACGAAGAAGGTGGACACCTCCGATCATGTG

81

81

TTLL12

NM_183017.2

1459-1558

TGCTGCGCTCAGTGAGGCCGCTGAGGTTGTTTGCTTACGATGTGTTTTGGCT
ACGCTTCTCCAATCGGCCCTTCGCCCTCGATGACCTAGACGACTATGA

81

82

TTLL13

NM_177765.3

977-1076

TATGATCTGCCAGCAGTACATCACCAAGCCCTTCCTTATTGATGGCTTCAAGT
TTGACATGCGAATCTATGTTCTGATCACTTCCTGTGACCCTCTCCGG

81

79

TTLL3

NM_133923.6

676-775

AACGAAATGTTTCGGGAGTCGCAGCTGTTGGACTTGGATGGTTTCCTGGAAT
TTGATGACCTAGATGGGATACATGCTTTGATGTCCCGCATGGTTCGAA

81

79

TTLL4

NM_001014974.1

3335-3434

GCCTATTACTTGACCCAGAAAATTCCTGACCAGGACTTCTATGCGTCCGTGCT
GGACGTCTTGACACCAGATGATGTTCGGGTTTTGGTGGAGATGGAAG

82

82

TTLL5

NM_001081423.2

493-592

TCATGAAGTTCACCCGAGCAGCACTGACTATAATTTGATGTGGACAGGATCC
CACCTAAAACCGTTCTTACTTCGAACCCTCTCTGAAGCACAAAAGGTT

83

81

TTLL7

NM_027594.1

291-390

TTCCTGTGACTTGGGGCCATATTCTACTTAGATGAACTCGGAACTTCCAGCTT
TCCCGAGCGCTTGGCACTACAGGCAGGCTTCTTGCTTGCTTGGTATA

81

82

Tuba1a

NM_011653.2

1379-1478

GGGAGGAAGAAGGAGAGGAATACTAAATTAAATGTCACAAGGTGCTGCTTC
CACAGGGATGTTTATTGTGTTCCAACACAGAAAGTTGTGGTCTGATCAG

86

77

Tuba1b

NM_011654.2

1456-1555

AGTTGCAGGCACTGATGCTTCTGTGCTGTTTCCATTCTGTGATCATGTCTTCT
CCATGTTGTACCTCTTAAGTTTTCCATGATGTCTCAAAGTAAAAGCT

78

72

Tuba1c

NM_009448.4

447-546

GGACTCCTTGGTAGTCTGTTAGTGGGAGATCTTCGTCACCCTTTTTCACTTCC
TCAGTTTTCGCGGACCACTTCAAGGACTAAATATGCGTGAGTGCATC

77

80

Tuba4a

NM_009447.3

1342-1441

GGAAAAAGATTATGAGGAAGTAGGCATCGACTCCTATGAGGACGAGGATGA
GGGAGAAGAGTAGACCGCTACTTGGAGCCTGTTCACTGTGTTTATTGCA

85

83

Tuba8

NM_017379.1

1024-1123

CGGTGATGTGGTACCCAAGGACGTGAATGTCGCCATTGCTGCCATCAAGAC
CAAGAGAACTATTCAGTTTGTTGACTGGTGTCCCACAGGTTTCAAGGTG

82

78

Tubb2a

NM_009450.1

1378-1477

GAGGAGGAAGAGGGTGAAGATGAGGCTTGAGAACTTCTCAGATACAATGTG
CACCCTTAGTGAACTTCTGTTGTCCTCCAGCATGGTCTTTCTATTTGTA

87

75

Tubb2b

NM_023716.2

1439-1538

GAGGGCGAGGATGAGGCTTGAGTTCCCCAGGCCAAGCAGGTTAGGGAAAG
CTGAGATGAAAGGAGGGGGTGGGGGGGCTTAATCTGTGAAAATACCTTGG

88

89

Tubb3

NM_023279.2

180-279

CATCAGCGTATACTACAATGAGGCCTCCTCTCACAAGTATGTGCCCAGGGCC
ATTCTGGTGGACTTGGAACCTGGAACCATGGACAGTGTTCGGTCTGGC

84

83

Tubb4a

NM_009451.3

1820-1919

CCCCTCAACACATGTACACACACACACACACTCCACCTTCTTAGATCTTGAAA
ATCCTTTCCTTTATGCCCTGTCCCTTCCCCAGCACTCCTGAACCATT

83

80

Tubb4b

NM_146116.1

747-846

CATGAGTGGGGTAACCACTTGCCTGCGATTCCCTGGCCAGCTAAATGCTGAC
CTGCGGAAACTGGCTGTAAATATGGTGCCCTTCCCTCGCCTGCACTTC

85

84

Tubb5

NM_011655.4

2261-2360

ATTGGAAGTGTCTTCCCTGTATTGGTTCTCCTTTCTCGGAGAGATGGGGGTT
GGGGGTGCGGCAAGGTCTTGGTCTTGGTCTCTGAACACTCCCAATTCC

79

82

Tubb6

NM_026473.2

1303-1402

CAGGACGCCACGGTCAATGATGGGGAAGAGGCATTTGAAGACGAGGATGA
AGAAGAGATCAACGAATAGGGAGCCATAAGATGCTACAGTGAACGTCTGC

82

82

Vash1

NM_177354.4

1844-1943

GGAATTTACCTCACCAACAGTATGCCCACCCTGGAACGCTTTCCCATCAGCTT
CAAGACCTATTTCTCAGGGAACTACTTCCGCCACATTGTGCTGGGGG

84

83

Vash2

NM_144879.2

917-1016

GGCATCTATCTCACCAATGGGCAGCCTTCCATTGAGCGGTTCCCTATCAGCT
TTAAAACCTACTTCTCAGGAAACTACTTTCACCATGTCGTGCTGGGGA

81

79

Table 2: Mouse tubulin isoforms, tubulin modifying enzymes, and molecular motors
panel design and information.
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Customer
Identifier

Accession

Position

Target Sequence

Tm CP

Tm RP

Acta2

NM_007392.2

46-145

GGAACCCTGAGACGCTGCTCCAGCTATGTGTGAAGAGGAAGACAGCACAGC
CCTGGTGTGCGACAATGGCTCTGGGCTCTGTAAGGCCGGCTTCGCTGGT

82

82

Agrn

NM_021604.3

4249-4348

CAGAGGGACTGCTGCTCTACAATGGCAATGCACGTGGCAAAGATTTCCTGG
CTCTGGCTCTGTTGGATGGTCATGTACAGTTCAGGTTCGACACGGGCTC

82

82

Bax

NM_007527.3

736-835

CATAAATTATGACATTTTCCTGGGATGAATGGGGGAAGGGGAAAGGCATTTT
TCTTACTTTTGTAATTATTGGGAGGGGTGGGAATGGTGGCCTGGGGAG

82

81

Bcl2

NM_009741.3

1845-1944

GGCCTTCTTTGAGTTCGGTGGGGTCATGTGTGTGGAGAGCGTCAACAGGGA
GATGTCACCCCTGGTGGACAACATCGCCCTGTGGATGACTGAGTACCTG

85

87

Casp3

NM_009810.2

631-730

GAGGCTGACTTCCTGTATGCTTACTCTACAGCACCTGGTTACTATTCCTGGAG
AAATTCAAAGGACGGGTCGTGGTTCATCCAGTCCCTTTGCAGCATGC

83

78

Ctgf

NM_010217.2

2241-2340

GGCTCAGGGTAAGGTCCGATTCCTACCAGGAAGTGCTTGCTGCTTCTTTGAT
TATGACTGGTTTGGGGTGGGGGGCAGTTTATTTGTTGAGAGTGTGACC

82

81

Col14a1

NM_181277.3

785-884

GAGGTTCAACTTCAGGCTTGTGCGCAATTTCTTGGAAAACCTGGTCACAGCG
TTCAACGTGGGCTCAGAAAAGACAAGAATCGGCTTGGCACAGTACAGT

80

82

Col1a1

NM_007742.3

216-315

CAATGGTGAGACGTGGAAACCCGAGGTATGCTTGATCTGTATCTGCCACAAT
GGCACGGCTGTGTGCGATGACGTGCAATGCAATGAAGAACTGGACTGT

82

81

Col3a1

NM_009930.1

4371-4470

CAAGACAGTCTTTGAATATCAAACACGCAAGGCAATGAGACTACCCATCATA
GATATCGCACCCTATGACATTGGGGGTCCTGATCAAGAATTTGGTGTG

82

82

Col4a1

NM_009931.2

4117-4216

CTCCAGGGATCACAGGTTCAAAGGGAGATATGGGACTGCCCGGAGTTCCAG
GATTTCAAGGTCAGAAAGGGCTTCCTGGTCTGCAGGGAGTGAAAGGAGA

82

82

Col8a1

NM_007739.2

2936-3035

TCTGTAGTGCAGGGTCCATGGTAATCTCTAGTCCAAAGGATATTTCTCTGTGT
TAGAGGCAATGCTTTGAGCTGCAGGACTACCTAGTCAGAATTGTGTG

79

83

Creb1

NM_001037726.1

2735-2834

TTCTGTCTGGACAGTTCACCAGATTCTCCAGAAGGCTTTCAAACGGCTAAAG
TTTGATCTTTGTCCTGCTGAGCTTGCTGGGAAGGAGATAGCATAAAAG

80

81

Dag1

NM_010017.3

611-710

CCACCGTGGTTGGCATTCCAGACGGTACGGCTGTTGTCGGGCGCTCATTTC
GAGTGAGCATTCCAACGGATTTAATTGCCTCCAGTGGGGAGATCATCAA

82

81

Fasn

NM_007988.3

6561-6660

TTCTCCTCTGTAAGCTGCGGGCGTGGTAATGCTGGCCAAACTAACTACGGCT
TCGCCAACTCTACCATGGAGCGTATATGTGAACAGCGCAGGCACGATG

82

82

Fhl1

NM_010211.2

1991-2090

CGTTGTCTGCTCTTTGTCTGCATCCAGGAAGAGTGCAAAGTCCCTTTGCTTGT
GATTCTTAGAACTTTCCCTCCAGAATTGCAGTTAGACTCTGGGGCTG

80

80

Fhl2

NM_010212.3

963-1062

CCATTAGTGGTCTGGGTGGCACAAAGTACATCTCTTTCGAGGAACGCCAATG
GCACAACGACTGCTTTAACTGTAAGAAGTGCTCCCTGTCTCTGGTGGG

83

82

Fmod

NM_021355.3

1986-2085

GCTTTTAGTATCGAAGGGGCAAGCGTGGTTTTCAAAACATGAGAAAGAGCCT
CTGCTCATCCTTTGGTCTAGTATGAAGGGTTGTTACGCAAATGGCAGA

80

80

Fn1

NM_010233.1

2628-2727

TCCAGACCCTACCGTGGACCAGGTTGATGATACTTCCATTGTTGTTCGGTGG
AGTAGACCCCAGGCACCTATCACAGGGTATAGAATTGTCTATTCACCT

81

83

c-fos

NM_010234.2

1331-1430

AGCTGGTGCATTACAGAGAGGAGAAACACGTCTTCCCTCGAAGGTTCCCGT
CGACCTAGGGAGGACCTTACCTGTTCGTGAAACACACCAGGCTGTGGGC

82

82

Gapdh

NM_001001303.1

891-990

AGGTTGTCTCCTGCGACTTCAACAGCAACTCCCACTCTTCCACCTTCGATGCC
GGGGCTGGCATTGCTCTCAATGACAACTTTGTCAAGCTCATTTCCTG

81

79

Cx43

NM_010288.3

1451-1550

CTGGGGTGTTCATTTCGTTCCCGTGGAGGTGGTACTCAACAACCTCAGTAAT
GAGGCGTAGAAAACAAAGACATTACAATATCTAGGTTCCTTGGGGGGT

81

83

Lum

NM_008524.2

871-970

CGACGGGCTGGTCAACTTGACCTTCATTTATCTTCAACACAACCAGCTCAAA
GAGGATGCTGTCTCGGCTTCTCTGAAAGGTCTCAAATCACTAGAGTAC

80

82

c-Myc

NM_010849.4

631-730

CCCTCAACGTGAACTTCACCAACAGGAACTATGACCTCGACTACGACTCCGT
ACAGCCCTATTTCATCTGCGACGAGGAAGAGAATTTCTATCACCAGCA

83

78

Myh6

NM_010856.2

26-125

ACTGTGGTGCCTCGTTCCAGCTGTGGTCCACATTCTTCAGGATTCTCTGAAAA
GTTAACCAGAGTTTGAGTGACAGAATGACGGACGCCCAGATGGCTGA

82

82

Myh7

NM_080728.2

1133-1232

CCACGGATAGCGCCTTTGACGTGCTGGGCTTCACTCCAGAAGAGAAGAACT
CCATTTACAAGCTGACAGGCGCCATCATGCACTTTGGAAACATGAAGTT

85

81

Nfkb1

NM_008689.2

2126-2225

GTCTTACACTTAGCCATCATCCACCTCCACGCTCAGCTTGTGAGGGATCTGCT
GGAAGTCACATCTGGTTTGATCTCTGATGACATCATCAACATGAGAA

83

81

Nid1

NM_010917.2

735-834

AAAGCCAAGTACCTGCTGTGGTTGGTTTCAGCAAAGGTCTAGTAGGATTTCT
ATGGAAGAGCAACGGAGCCTATAACATATTTGCCAATGACAGAGAATC

80

82

Nppa

NM_008725.2

691-790

CTATCACGATCGATGTTAAATGTAGATGAGTGGTCTAGTGGGGTCTTGCCTC
TCCCACTCTGCATATTAAGGTAGATCCTCACCCTTTTCAGAAAGCAGT

80

80

Nppb

NM_008726.4

177-276

GCTTCTGCGGCATGGATCTCCTGAAGGTGCTGTCCCAGATGATTCTGTTTCT
GCTTTTCCTTTATCTGTCACCGCTGGGAGGTCACTCCTATCCTCTGGG

83

81

Nppc

NM_010933.5

428-527

ACAAAGGCGGCAACAAGAAGGGCTTGTCCAAAGGCTGCTTTGGCCTCAAGC
TGGACCGGATCGGCTCCATGAGCGGTCTGGGATGTTAGTGCAGCTACCC

84

85

Osf2

NM_015784.2

760-859

GACCTTTCATCATTTAGAGCAGCCGCCATCACCTCTGACCTCTTGGAGTCCCT
TGGAAGAGATGGTCACTTCACGCTCTTTGCTCCCACCAATGAAGCTT

82

83

Rcan1

NM_001081549.1

1061-1160

ACACAAGGACACTGGGGACATCCTGAGAAAACTGATAGTTCTTGTAATTGCT
CATTTCTAGGTTCTGTTTTTGGCAAGGACAGGTTGACTGGTGGCCCAG

82

79

Rpl4

NM_024212.4

308-407

CCAGGGTGCCTTTGGAAATATGTGTCGTGGGGGACGCATGTTTGCACCAAC
CAAAACCTGGCGTCGTTGGCACCGCAGAGTGAATACAACCCAAAAACGA

84

86

Sod2

NM_013671.3

1496-1595

ATAGCTTTGCTCCTGCTTGAGGAGTGCTTATTATGAGAGGAAGGTAATGGTG
CCTCTGGGTTTTCTATAGGCAGACATGCAAAAACAGCTAATCTTGTCT

82

80

Srf

NM_020493.2

3316-3415

AGCCAGCCTAAACCACCTGTATCCATTAAAGGAGCTTTTTCCGGGAGGGCAG
TTGGGGTAGGGTGTCACTAAACCCTTGTTGCTGCCTTCAGTAGGAACA

83

82

Tbp

NM_013684.3

71-170

GTGGCGGGTATCTGCTGGCGGTTTGGCTAGGTTTCTGCGGTCGCGTCATTTT
CTCCGCAGTGCCCAGCATCACTATTTCATGGTGTGTGAAGATAACCCA

83

79

Tgfb

NM_011577.1

1471-1570

GGAGTTGTACGGCAGTGGCTGAACCAAGGAGACGGAATACAGGGCTTTCG
ATTCAGCGCTCACTGCTCTTGTGACAGCAAAGATAACAAACTCCACGTGG

82

78

Thbs4

NM_011582.3

1129-1228

CGTGGATGAGTGCAAATACCATCCCTGCTATCCAGGTGTGCGCTGTGTGAAT
TTGGCTCCGGGTTTCAGATGTGACGCCTGTCCAGTAGGTTTCACAGGG

84

82

TIMP-1

NM_011593.2

437-536

AAGCCTCTGTGGATATGCCCACAAGTCCCAGAACCGCAGTGAAGAGTTTCTC
ATCACGGGCCGCCTAAGGAACGGAAATTTGCACATCAGTGCCTGCAGC

83

83

TIMP-2

NM_011594.3

656-755

TTGCAGGAAAGGCAGAAGGAGATGGCAAGATGCACATTACCCTCTGTGACT
TCATTGTGCCCTGGGACACGCTTAGCATCACCCAGAAGAAGAGCCTGAA

82

82

TIMP-3

NM_011595.2

2461-2560

GTCACTTCCGGAGGTGGTCACCTCATAGAATGAACATGATTGGTTACTGAGG
GAGCCAGGCTCTGCCGTCCAAATGTAGGCCTTTTGTTGTGTTGTATTT

82

79

TIMP-4

NM_080639.3

326-425

GAAGGCCAAGGATATTCAGTATGTCTACACGCCATTTGACTCTTCCCTCTGTG
GTGTGAAGCTAGAAACCAACAGTCACAAGCAGTATCTTTTGACTGGC

80

82

Tnnc1

NM_009393.2

58-157

CAAAGCTGCGGTAGAACAGTTGACAGAGGAGCAGAAGAATGAGTTCAAGG
CTGCCTTTGATATCTTTGTCCTGGGCGCGGAGGATGGCTGCATCAGCACC

84

83

Tnni3

NM_009406.2

211-310

GAGCCTATGCCACCGAGCCACACGCCAAGAAAAAGTCTAAGATCTCCGCCT
CCAGAAAACTTCAGTTGAAGACTCTGATGCTGCAGATTGCGAAGCAGGA

82

79

1387-1486

AGTGTGGAGGAGGTCTACTTGGGGTGAGAACCCTGTATCGTTTTGAGAACC
AGACATGCTTCCCTCTCCCTGATAGCAGATTTGATGCCTACTGCTTTAA

82

80

Vcan

NM_172955.1

Table 3: Mouse hypertrophy and fibrosis panel design and information.
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Customer
Identifier

Accession

Position

Target Sequence

Tm CP

Tm RP

GAPDH

NM_001001303.1

891-990

AGGTTGTCTCCTGCGACTTCAACAGCAACTCCCACTCTTCCACCTTCGATGCC
GGGGCTGGCATTGCTCTCAATGACAACTTTGTCAAGCTCATTTCCTG

81

79

Rpl4

NM_024212.4

308-407

CCAGGGTGCCTTTGGAAATATGTGTCGTGGGGGACGCATGTTTGCACCAAC
CAAAACCTGGCGTCGTTGGCACCGCAGAGTGAATACAACCCAAAAACGA

84

86

Tbp

NM_013684.3

71-170

GTGGCGGGTATCTGCTGGCGGTTTGGCTAGGTTTCTGCGGTCGCGTCATTTT
CTCCGCAGTGCCCAGCATCACTATTTCATGGTGTGTGAAGATAACCCA

83

79

Ttc5

NM_001080949.2

33-132

ATGATGGCTGATGAAGAGGAAGAAGCGAAGCACGTCTTGCAGAAATTGCAG
GGACTGGTGGATCGGCTCTACTGTTTTCGAGACAGTTACTTTGAGACAC

82

83

1379-1478

GGGAGGAAGAAGGAGAGGAATACTAAATTAAATGTCACAAGGTGCTGCTTC
CACAGGGATGTTTATTGTGTTCCAACACAGAAAGTTGTGGTCTGATCAG

86

77

Tuba1a

NM_011653.2

Tuba1b

NM_011654.2

1456-1555

AGTTGCAGGCACTGATGCTTCTGTGCTGTTTCCATTCTGTGATCATGTCTTCT
CCATGTTGTACCTCTTAAGTTTTCCATGATGTCTCAAAGTAAAAGCT

78

72

Tuba1c_exon

NM_009448.4

240-339

CCACCTGGCCCTGGCGTGGACCCTGGGTGTCTCCTCCCCTTCCCACTTCCAG
CTCCTTCTACGGAGTTTGATTTGAACTTTCGAACCCGCCAATCATCGG

89

77

Tuba1c

NM_009448.4

447-546

GGACTCCTTGGTAGTCTGTTAGTGGGAGATCTTCGTCACCCTTTTTCACTTCC
TCAGTTTTCGCGGACCACTTCAAGGACTAAATATGCGTGAGTGCATC

77

80

Tuba4a

NM_009447.3

1342-1441

GGAAAAAGATTATGAGGAAGTAGGCATCGACTCCTATGAGGACGAGGATGA
GGGAGAAGAGTAGACCGCTACTTGGAGCCTGTTCACTGTGTTTATTGCA

85

83

Tuba4a_ex_ex

XM_006496478.2

1997-2096

AAACTGGAGCTGGAAAACATGTGCCTCGGGCAGTCTTTGTGGACCTGGAGC
CTACTGTAATCGATGAGATCCGAAATGGCCCATACCGTCAGCTCTTCCA

89

83

Tuba8

NM_017379.1

1024-1123

CGGTGATGTGGTACCCAAGGACGTGAATGTCGCCATTGCTGCCATCAAGAC
CAAGAGAACTATTCAGTTTGTTGACTGGTGTCCCACAGGTTTCAAGGTG

82

78

1450-1549

TGGAGAAGGATTATGAAGAAGTGGGGACTGATTCGTTTGAAGAAGAGAATG
AGGGGGAGGAATTTTAAATATACACTTGCCCCATGACTATGCCTCTTTC

83

81

Tuba8_2

XM_036166283.1

Tubb1_ex_ex

NM_001080971.2

282-381

GGAGAGGATCAGCGTTTACTACAACGAAGCCTACGGTAAGAAGTATGTGCC
GCGAGCCGTCCTTGTGGACCTGGAACCCGGGACAATGGACAGCATCCGA

85

89

Tubb1

NM_001080971.2

481-580

GAGCTGATCGAAAATGTCATGGATGTGGTAAGGAGGGAGAGCGAGAGCTG
CGACTGCCTACAGGGTTTCCAGATCGTGCATTCTCTGGGTGGAGGCACGG

90

87

87

75

87

89

88

89

88

89

Tubb2a

NM_009450.1

1378-1477

GAGGAGGAAGAGGGTGAAGATGAGGCTTGAGAACTTCTCAGATACAATGTG
CACCCTTAGTGAACTTCTGTTGTCCTCCAGCATGGTCTTTCTATTTGTA

Tubb2a_exon

NM_009450.2

2-101

GGTCTTTTGCGCTCCTTAGCCCTCTGTCCACGCACTGCTCCGAGGGCAAGAG
CCTCCACCCCTTCTACAACCAGCACCATGCGCGAGATCGTGCACATCC
GAGGGCGAGGATGAGGCTTGAGTTCCCCAGGCCAAGCAGGTTAGGGAAAG
CTGAGATGAAAGGAGGGGGTGGGGGGGCTTAATCTGTGAAAATACCTTGG
AGGAGGGGGAGATGTATGAAGATGATGACGAGGAATCGGAAGCCCAGGG
GCCCAAGTGAAGTTGCTCGCAGCTGGGGTGTGGGGCCAAGTGGCAGCCAG
G
CGCATCAGCGTATACTACAATGAGGCCTCCTCTCACAAGTATGTGCCCAGGG
CCATTCTGGTGGACTTGGAACCTGGAACCATGGACAGTGTTCGGTCTG

Tubb2b

NM_023716.2

1439-1538

Tubb3 2

NM_023279.3

1348-1447

Tubb3_ex_ex

NM_023279.3

189-288

85

88

Tubb4a

NM_009451.3

1820-1919

CCCCTCAACACATGTACACACACACACACACTCCACCTTCTTAGATCTTGAAA
ATCCTTTCCTTTATGCCCTGTCCCTTCCCCAGCACTCCTGAACCATT

83

80

33-132

GCCACAGCGGCCGGTCGACACCCGTCCATCAGACGCCACCAGCAGCGCCA
CCACCATGCGGGAAATCGTGCACCTGCAAGCCGGTCAATGCGGTAACCAG

89

90

Tubb4a_exon

NM_009451.4

Tubb4b

NM_146116.1

747-846

CATGAGTGGGGTAACCACTTGCCTGCGATTCCCTGGCCAGCTAAATGCTGAC
CTGCGGAAACTGGCTGTAAATATGGTGCCCTTCCCTCGCCTGCACTTC

85

84

Tubb4b_exon

NM_146116.2

1-100

GGCGGGTCATAAGAGGTATATAAATGTTGGCAGAGCGTCGGTTGTAGCACT
CTGTGCGCCTGCTCCTCCCGAAGTGCTCCTCTTCTACAGCTGTTCCGCA

83

87

Tubb5

NM_011655.4

2261-2360

ATTGGAAGTGTCTTCCCTGTATTGGTTCTCCTTTCTCGGAGAGATGGGGGTT
GGGGGTGCGGCAAGGTCTTGGTCTTGGTCTCTGAACACTCCCAATTCC

79

82

Tubb5_intron

Tubb5_int.1

253-352

TGTGAAGAGCTGGTCTTAAAAGGGGTTTTCTAACGGTTCGAGGACTGGAGG
GATGCGGAAACGATCCGAGACAAAGCCGAGGCGAGGTTTTCCCCTTGCG

83

87

Tubb6

NM_026473.2

1303-1402

CAGGACGCCACGGTCAATGATGGGGAAGAGGCATTTGAAGACGAGGATGA
AGAAGAGATCAACGAATAGGGAGCCATAAGATGCTACAGTGAACGTCTGC

82

82

Tuba1a_intron

Tub_14.1

1074-1173

GCTGGAAATAGAGCTTTCTCTGTTAAATAATGTAACAGCACAGGCTAGCACC
AGGCACAGAGAACGTGGCAATGCAGAAATCAGACTTTGTCTAGCTTGT

81

85

445-544

TAGGGTGTGTCTCCAGTTGGATCCTTGTTTTGAGCTCAGGGTCTAACGCAGG
ATCTCTACCATTTTAACTCAGCTATTACCGAGTTGCGGTCTCACCCGC

81

80

Tuba1b_intron

Tub_15.1

Tuba1c_intron

Tub_16.1

940-1039

TCTGTCTCCACTACCCAAGAGCTAGGGTTATTCACCTGGTTAACAATGTATTA
GTTCAGTTTTCAAGAAAAAAATGGGTGAGGCTATCAAACCCTGGGCT

81

79

Tuba4a_intron

Tub_17.1

29-128

TGAGGAAAGTGGAGTGTCTCTTGAAGAATGTCTTGGCTGGGTTTTTGTGATC
TTTGAAGCCTCTTGGTTTATTTGAAGCTGAAGATGGATGCTGGCAGAA

79

79

Tuba8_intron

Tub_18.1

311-410

TGGTGGTATCCTGGGAAGCTTTCAGCCGTATGTGAGGTTGAAGTTAGGAAC
AAAGGTGAGTAAAGCTTTTGTTGGAAAGAAGTGAGGAAGAGATTTGAGC

83

80

Tubb1_intron

Tub_19.1

227-326

TGCTGAGACAACGAGCTAGACACACAGGAAAGACAGAAGTAGAGTTTTTAA
AAGGTATTTTTACAGATCCATGTCATGGTGGGCTGGGTCAGATACGATC

85

80

Tubb2a_intron

Tub_20.1

390-489

TGAATGAAAAAAATGCAGTGTCATTGGGTTGACAGATGTTACAGAGGCGTGT
CTTTGGGCCAACAGACGAGGGTGTTAGACAAATTCTCTTACAAGGGCT

80

83

Tubb2b_intron

Tub_21.1

316-415

CACAGGAGAATTGATTTTACTCGCTTGATCACCAGGCGAGCTGCGGGGGAG
GGGAGGAAGAACGATTGCCAGACGGTCACTGAACGTGCTTTGAATTTAA

86

83

233-332

GACCTTATGTAGTCTAGGGACAGGCAGGAGACTCAATGATACATCCTTAGCA
GGGGTCACTGGGGGCTTGATTGAGGCTACTTGATAATTGATACAGTCT

85

85

Tubb3_intron

Tub_22.1

Tubb4a_intron

Tub_23.1

308-407

CCCCAACTTCTCCCTTCTTGCTGGCTCATGCTTTGCTGTGGCTCTGAGTTCCC
AGTTACCTCACAGACAGACAGTCAGCAACTGAAGAAGTGGCTTTAAG

82

85

Tubb4b_intron

Tub_24.1

100-199

TACCGGCGTACGCTGGGCCGAGACGTAGCGCCGGTGGCTGGTGTCGGTGG
GGCGGACGGTGCGCGGCCCTTAGGGATTCGTCGCCCTGGCGCTCCTGAGA

89

89

495-594

TTCATCGGGCGCCAAAACTGTAGACAGCTCTAAGAAATTAATGGGGAAATTA
GCAAAATTCTAGACTCTGGATAATCCCAGTTTGGGAATAATAGCACCT

83

80

Tubb6_intron

Tub_26.1

Table 4: Mouse tubulin isoforms exons and introns (autoregulation) panel design and
information.
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Customer
Identifier
GAPDH

Accession
NM_001256799.1

Position

Target Sequence

Tm CP

Tm RP

387-486

GAACGGGAAGCTTGTCATCAATGGAAATCCCATCACCATCTTCCAGGAGCGA
GATCCCTCCAAAATCAAGTGGGGCGATGCTGGCGCTGAGTACGTCGTG

85

86

81

83

RPL4

NM_000968.2

863-962

AGCCGCTTCCCTCAAGAGTAACTACAATCTTCCCATGCACAAGATGATTAATA
CAGATCTTAGCAGAATCTTGAAAAGCCCAGAGATCCAAAGAGCCCTT

TBP

NM_001172085.1

588-687

ACAGTGAATCTTGGTTGTAAACTTGACCTAAAGACCATTGCACTTCGTGCCC
GAAACGCCGAATATAATCCCAAGCGGTTTGCTGCGGTAATCATGAGGA

79

82

213-312

TGGTGGTATGTTTTGTGAGGTTTAGCTTAGCCCCAAATCCTCAAGCCCCGCC
GCCGCCGCAGTGCGGGTGCAGGAACCGGGCCAGTACTGCGCCCAGGGC

80

93

86

85

tuba1a_ex

NM_001270399.2

tuba1a_in

Ar_tuba1a_in.1

761-860

CTGTTAAATAATGTAGCAGACAGTACAGGCTAGCACCAGGCACAGCAAATAC
AGCAATGCAGCAATGCAGAAGGCAGACCTTGTCTAAACTCCTAGTATT

tuba1c_ex

NM_032704.5

2641-2740

CACTACACCTGGCCCCTAGATACGTTTTTTAATAACCTCCCAAATGATGCTGT
TGGTCTGATGTGACCACATGTACAGTAGCAAAGGGTTAGATAACAGT

79

82

1348-1447

GGTAAGTCAGTGGCCGCTGACTGCCTGCTAAGCTTCAAGAAGGCAGTTTAG
ACTGAGCAATGAAAGAAAAATTGCGGGCGCAAAATAGAAACGGCATTTA

86

82

86

83

tuba1c_in

Ar_tuba1c_in.1

tuba4a_ex

NM_006000.3

209-308

CCACCTTCTTCTGTGAAACTGGTGCTGGAAAACACGTACCCCGGGCAGTTTT
TGTGGATCTGGAGCCTACGGTCATTGATGAGATCCGAAATGGCCCATA

tuba4a_in

Ar_tuba4a_in.1

834-933

TCACCGCAGGTTCCACTTCCTTTCTGGGTATTTGGAAACCGTCACCCCGCCAT
TTCGGTGTGGGAAGAGCGCGCGGGCCCTGCCGGACTTTAGTGCTTTA

82

84

81

92

tuba8_ex

NM_001193414.2

405-504

CAGATGCTTGCTCTGGCCTGCAGGGCTTCCTGATTTTCCACAGTTTTGGTGG
GGGCACTGGCTCCGGCTTCACTTCTCTGCTGATGGAACGCCTCTCCCT

tuba8_in

Ar_tuba8_in.1

441-540

ACATATATTATTGCCACCATGAGGTGGAGTTGAGGGGTGGGACAACTCTTG
GGGGTCTAGGTTCTGGGCAGATCATCCTGAATCTTTCTCCATGTCCCTA

84

83

tubb_ex

NM_001293214.2

1581-1680

CCATTCTGGGTGACCCTGTATTTCTTTCTGGTGCCCATTCCATTTGTCCAGTTA
ATACTTCCTCTTAAAAATCTCCAAGAAGCTGGGTCTCCAGATCCCA

75

79

91

91

tubb1_ex

NM_030773.4

993-1092

TGGCTGCCTGTGACCTCCGCCGTGGCCGCTACCTCACAGTGGCCTGCATTTT
CCGGGGCAAGATGTCCACCAAGGAAGTGGACCAGCAACTGCTCTCCGT

tubb1_in

Ar_tubb1_in.1

1012-1111

GATAATACGGAAAGGGGCCCTCAAGAGAAAGTGTTAGGTTTAGATAGGGTT
TTAGCTCTCACTCTGGAATCGTATGGTCTAGCGTTGAGAGTCCTGGCTG

84

82

tubb2a_ex

NM_001310315.2

1530-1629

GGAGGGCGAGGACGAGGCTTAAAAACTTCTCAGATCAATCGTGCATCCTTA
GTGAACTTCTGTTGTCCTCAAGCATGGTCTTTCTACTTGTAAACTATGG

85

76

87

85

93

92

tubb2a_in

Ar_tubb2a_in.1

355-454

tubb2b_ex

NM_178012.5

32-131

tubb2b_in

Ar_tubb2b_in.1

30-129

GAAAACATGCAGTGTCACTGGACTGGCAGATGTAACAGAGGCGTCCCTTTG
GGTCGTACAGGCAAGGGTGTTAGATAAATTCCCTTGCTCGGGCACTGTC
GTGACCCCGCAGTGGGTGTGTGAGGGGAGGACGGACAGACCCAGACGCC
GCCGGACCAGGAGGACGCTGACGAGGCACCATGCGTGAGATCGTGCACAT
C
GGGATTCATTTTACGCTGGGCAGTGGAGGCTGAAGAGGTGTGATTGCCAGA
GGGAAAGCATGAAGAACATCCGCGGTGTGCCAACTTAGCTTTAATATAG

86

82

91

88

tubb3_ex

NM_006086.4

143-242

ATGGCATCGACCCCAGCGGCAACTACGTGGGCGACTCGGACTTGCAGCTGG
AGCGGATCAGCGTCTACTACAACGAGGCCTCTTCTCACAAGTACGTGCC

tubb3_in

Ar_tubb3_in.1

316-415

CCTGGAGGGCTTAGTCAGGGGCTCTTTAGCAACTGGTGTGAAGTGATTTCCA
TATCAAAGTGGTGATACACCCACCTGCCCACATGGACATGTGATTTAA

85

82

tubb4a_ex

NM_006087.4

1510-1609

AGAGCCCCGCTTTCCCTCCAAGGCTGACTCCCCGCTGACCCTAACAATACCT
TTGGAGCTCGCTTTACCTCTGGCTACTTCATCTCCGACCCTGGCTCCC

92

85

86

86

tubb4a_in

Ar_tubb4a_in.1

623-722

TATCTGCAGTCTAGAATGTGAGTAGGATTTGGACTGGCCAAAGGGCATGGA
AGGGAGGAAAGATGTTTAAGACGGAGGCAACAGCATATGTGAAGATAGT

TUBB4B_ex

NM_006088.5

381-480

TCAGAGTGGTGCTGGGAACAACTGGGCCAAGGGGCACTACACAGAAGGCG
CGGAGCTGGTGGACTCGGTGCTGGATGTTGTGAGAAAGGAGGCTGAGAGC

93

92

tubb4b_in

Ar_tubb4b_in.1

268-367

GGGGTTTGTTAAGCTGTCAGGTTTGGCCCCTGACTTAATTCGTAGCAGGGCA
GGCTGCCGTCTTTTGGCTTTGAAGGGTCCGTTTGCTCTACCTCCAGGG

81

83

93

87

tubb6_ex

NM_001303528.2

1446-1545

GGATGCCACCGCCAATGACGGGGAGGAAGCTTTTGAGGATGAGGAAGAGG
AGATCGATGGATAGTCGGAATAGAGCCGCCCCAACTCAGATCCTACAACA

tubb6_in

Ar_tubb6_in.1

842-941

TTCCATGGAGCTAAAGTTGTAAAACTTCCTAACAGGAAAGAGGTGTCAGGGT
GAGCTGGAAAATACAGTAGGCAGGAAGTCAGGGGACTTGATTTCTCAT

82

85

100-199

ATCTGTCATTTTGTCCCTTTCGTGAACCACCGTCGGGGCCAAAGACGTCTGC
TGCCACCTGGTGGCGGGACCTGGAATGACAAGTCTCTGATCCCTGCTG

79

92

tubb_in

Ar_tubb_in.1

Table 5: Human tubulin isoforms exons and introns (autoregulation) panel design and
information.
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